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1.-Introduction 
 
1.1. - Epidemiology of suicide 
 
According to the data provided by the World Health Organization 
(WHO), more than 800,000 people die each year by suicide (World 
Health Organization, 2014); this represents a suicide every 40 
seconds. Other estimates suggest that 5% of adults will attempt 
suicide at any point in their lives (Nock MK et al., 2006). However, 
these figures only represent part of the problem, as, for every suicide 
committed, between 8 and 25 non consummated suicide attempts take 
place, although these figures vary depending on age. (Oquendo MA et 
al., 2009). Nevertheless, the lack of reliable national and international 
statistical data hinders a thorough understanding of the real extent of 
the problem.  
 
According to the National Institute of Statistics (Instituto Nacional de 
Estadística - INE), suicide was by far the main external cause of 
mortality in Spain in the year 2012, followed by traffic accidents (INE, 
2012). In 2013, the last year with available official figures, a total of 
3,870 persons took their lives, which implies a 22% rise when 
compared with the year 2010 in which the number of cases was 3,158, 
the highest figure ever recorded in Spain in the last 24 years 
(Sanmartín OR, 2015). Even though suicides decreased in the first few 
 years of the economic crisis, from the year 2010 they started rising 
again. This rise was very slight in the first year but in 2012 that figure 
had gone up by 11.3%, whereas in the year 2013, it rose again by 9% 
(Sanmartín OR, 2015). In some autonomous communities such as 
Catalonia though, suicidality increased by 44.7% from the onset of the 
crisis (Mouzo J, 2015). 
 
Figure 1.Evolution of suicides in Spain from 1995 until 2013  
*Source: adapted from INE, 2014 
 
In the last decades there has been an increase in suicidal behaviours 
in most eastern countries (García-Resa E et al., 2002). From the year 
2007 until 2009, coinciding with the onset of the economic crisis, the 
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proportion of suicides in Europe experimented a remarkable increase, 
inverting the downward trend that was predominant until 2007. It is 
precisely in those countries where the crisis has had a more profound 
impact, such as Greece, Ireland or Spain that the number of suicides 
has increased (Stuckler D et al., 2011). In European Union countries 
nearly 60,000 people die each year by suicide (European Commission, 
2008). In spite of the significance of those figures, it is thought that 
the real number has been underestimated (Hawton K et al., 2004). 
According to the data of the Organization for Economic Cooperation 
and Development (OECD, 2013), there are significant differences in 
the suicide figures for different countries. Figure 2 shows these 
differences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Suicide in different countries  
 
*Source: adapted from OECD, 2010 
Introduction 
 
17 
The estimation of suicide attempts involves several methodological 
difficulties, as it is a very heterogeneous group of patients which 
encompasses aspects which are difficult to determine such as 
planning, choice of method and lethality, and the real suicidal intent 
(Mittendorfer E et al., 2009). On the other hand, using different 
definitions of what a suicide attempt is also contributes to the 
confusion as there are discrepancies about the definition of suicidal 
behaviour and its consequences. Perhaps that is why different terms 
have emerged such as consummated suicide, parasuicide, voluntary 
self-injury, etc, which respond to the different manifestations of that 
behaviour. Different denominations have been proposed, among others 
the one developed by O´Carroll (O'Carroll PW, 1996) in 1996 and later 
recommended by the American National Institute of Mental Health in 
its research programme about suicidal behaviour (García-Resa E et al., 
2002). The consummated suicide would refer to self-inflicted death 
with evidence (explicit or implicit) that the person wanted to take their 
life; the suicide attempt would refer to deliberate and direct self-injury 
with at least some intention of taking their life and finally suicidal 
ideation would make reference to the thought of provoking their own 
death (Nock MK et al., 2009).  
One of the most important studies promoted by the WHO to prevent 
suicidal behaviour was developed at the beginning of the 21st century. 
 An extensive collection of data was carried out in the six regions of the 
WHO (Africa, America, Southeast Asia, Europe, East of the 
Mediterranean and West Pacific) and several groups of researchers 
conducted a plethora of studies based on those data in the following 
years (Bertolote JM et al., 2005; Bertolote JM et al., 2010). Those data 
suggest that there is not always a chronological continuation between 
the appearance of the idea of death and the suicide attempt and that 
the aspects related to the suicidal conduct may vary according to the 
place where they are assessed. 
 
1.2. Risk factors 
 
Usually, risk factors in suicidal behaviour have been classified into 
two groups, those which are modifiable and those which are not. 
Modifiable factors have social, psychological and psychopathological 
origin and may be altered in the clinic or through population 
interventions (García-Resa E et al., 2002). On the other hand, non-
modifiable risk factors have nothing to do with the clinical situation of 
the patient nor with their life circumstances, on the contrary, they are 
associated with the patient themselves or with the social group to 
which the person belongs. They are usually long-lasting and even 
though some of them suffer variations, such as age, marital status or 
religious beliefs, they change independently from the clinical situation 
(González-Navarro MD et al., 2012). It is necessary, therefore, to know 
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well both types of risk factors in order to carry out a precise 
assessment of the suicide risk in each patient. Additionally, it is 
important to include the protective factors in the assessment and 
prevention of the risk of suicide (Ayuso-Mateos JL et al., 2012). 
 
1.2.1. Non-modifiable risk factors  
 
1.2.1.1. Heritability 
It was observed long ago that some families have a higher suicide 
risk than others. This family predisposition is not only attributed to the 
existence or not of a psychiatric illness, as those relatives with a 
mental condition do not always have a higher risk of suicide than those 
who are healthy (Brent DA et al., 2005). In a meta-analysis of 21 
studies, it was observed that first degree relatives of people who had 
committed suicide had a three-fold higher suicide risk even without 
having a psychiatric pathology (Baldessarini RJ et al., 2004); When 
this pathology existed, the adjusted risk was 10 times higher for 
suicide and suicide attempts (Kim CD et al., 2005). In another study, it 
was considered as well that among first degree relatives who had 
attempted suicide (schizophrenia, 195; bipolar disorder, 315), the 
suicide risk was up to 8 times higher than in the comparison group  
(Tsuang MT, 1983). Endogamous populations like the Amish 
community in the United States, are perfect to conduct these studies; 
 this community has been the object of analysis of the transmission of 
affective disorders and suicides over 100 years, from 1880 until 1980 
(Egeland JA et al., 1985).  This analysis revealed that affective 
disorders were transmmitted and that 75% of the completed suicides 
within the Amish population, 26 in total, were limited to four families. 
 
The study of twins and adopted siblings is another way of analyzing 
the famiy transmission of suicide and associated behaviour. With this 
approach, it has been appreciated that the frequency of suicide is 
greater among homozygous twins than between heterozygous twins 
(Roy A et al., 1995; Statham DJ y et al., 1998).  The influence of 
genomic imprinting in suicide and suicide attempts is very high; 
different authors estimate that 43% of suicidal behaviour could be 
explained by this, while another 57% would respond to environmental 
factors (Roy A et al. 1995). 
 
All in all, it seems that genetic inheritance is one of the main factors 
that predispose to suicidal behaviour. Thus, the transmission of this 
behaviour seems to be conditioned by, at least, two components: one 
of them would be the transmission of mental diseases itself, and the 
other, the genetic load related to impulsivity and other personality 
factors (Brent DA et al., 2005). According to many studies, the family 
association is apparently bigger depending on the seriousness of the 
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suicidal behaviour, being lower in the case of suicidal ideation, higher 
for suicide attempts and much higher in the case of consummated 
suicide (Baldessarini RJ, 2004). 
 
1.2.1.2. Gender 
 
There are variations in the etiology, risk level and the origin of the 
suicidal behaviour, as well as in its prevention and treatment, 
depending on the gender of that person (Hawton K, 2000). In most 
countries except for China and other Asian countries, the suicide risk is 
bigger in men than in women (Zhang J et al., 2005). However, the risk 
of suicide attempts is usually higher among women than men (Miret M 
et al., 2010). The prevalence of mental disease is high in attempted 
and completed suicides both among men and women. It has been 
observed when studying behaviour, personality and emotional state 
previous to the decease that depressive disorders stand out in the 
suicide of both genders. Coexistence with a personality disorder has 
also been detected in 40-50% of the cases (Foster T et al., 1997). The 
types of mental illness are different depending on the gender. Men 
show a higher incidence of personality disorders and disorders related 
to the consumption of toxic substances while women show a higher 
prevalence of affective disorders, above all depression (Arsenault-
Lapierre G et al., 2004). In attempted suicide there are common 
 factors for both genders, such as suffering from a mental disease but 
others are gender-specific, like having low economic status, more 
linked to suicide risk for men or possessing low educational level, 
which increases the risk of attempting suicide for women (Zhang J y et 
al., 2005). 
 
Concerning maternity, having a little child (Qin P et al., 2003) or 
being pregnant (Marzuk PM et al., 1997) have been identified as 
protective factors. Thus, it would be maternity or paternity rather than 
the fact of living together that would protect against suicide (Qin P et 
al., 2000). On the contrary, the death of a child is associated with a 
higher suicide risk on the part of the mother (Qin P et al., 2003). 
However, post-partum depression constitutes an exception to the 
above mentioned protective character of maternity as in this case, the 
suicide risk increases (Appleby L et al., 1998). 
 
1.2.1.3. Age 
 
The risk of suicide also increases with age (Shah A, 2011). The 
process of growing old goes hand in hand with worse health, whether 
physical or mental. In adult age and above all, during old age, 
interpersonal losses are common and added to this, old people are 
part of a less active and fruitful social group. Ageing brings along a 
change in behaviour. In advanced age, we can notice that the quotient 
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of suicide and attempted suicide increases progressively (Conwell Y et 
al., 2001). 
 
1.2.1.3.1. Adolescents and young adults 
 
Suicide is among the first causes of death among young people and 
adolescents (INE, 2012). Thus, the figures of potential lifetime years 
lost are very high (Doessel DP et al., 2009). Mental disease is again, 
also at this age, one of the key risk factors and major depression the 
most frequent disorder associated to completed and attempted 
suicides. Other factors present at this age are substance consumption 
and behaviour disorders (Beautrais AL, 2000). Among young people 
dead by suicide comorbidity seems the norm, with a prevalence of 
psychiatric disorder of 43%-70% (Beautrais AL, 2000). Also,the higher 
the number of diagnoses, the more serious the attempts (Beautrais AL 
y et al., 1996). Another remarkable factor is the influence of 
inheritance in the suicidal behaviour of young people. Thus, the suicide 
risk is bigger among young people with a family history of psychiatric 
pathology (Brent DA et al., 1994); it is estimated that approximately 
half of suicide attempts may be attributed to familial psychopathology 
(Mittendorfer-Rutz E et al., 2007). In keeping with this, a background 
of parental suicidal behaviour has been related to an increase in the 
risk of sucide and attempted suicide (Gould MS et al., 1996). 
 
 
A higher risk of suicide has been detected among youths with low 
self-esteem, hopelessness, introversion, neuroticism, impulsivity, 
imprudence, aggressiveness and impulsive violence (McGirr A et al., 
2008). Another studied variable in the suicidal behaviour of young 
people has been their sexual orientation. There are several studies 
which identify a higher risk of attempting suicide in young people with 
homosexual or bisexual orientation (Meyer IH et al., 2008). However, 
such connection has not been found in consummated suicide (Shaffer 
D et al., 1996). A personal background of attempting suicide is also 
related to a higher risk of consummating suicide. One third of the 
suicide cases among children below 14 years old had a background of 
suicide attempts (Dervic K et al., 2008) and the figures are quite 
similar between adolescents and young people (Gould MS et al., 
1996). Several studies have also analysed the existing relationship 
between suicide attempts and social status. According to these studies 
suicide risk doubles in the case of young people with low 
socioeconomic status (Agerbo E et al., 2002), it is five-fold among 
those who have dropped out of school and almost eight-fold among 
those without higher education (Gould MS et al., 1996). Most of the 
suicides that were completed by adolescentes, between 70% and 
98%, were associated with a previous stressful life event (Rich CL et 
al., 1991). Among these life events the most frequent ones are losses, 
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interpersonal conflicts, and discipline or legal problems, which are 
present not only in suicides (Brent DA et al., 1994) but also in suicide 
attempts (Donald M et al., 2001).  
 
Family breakup, more specifically parents´separation, also seems to 
give rise to an increase in suicide risk (Agerbo E et al., 2002). The 
relation between suicide attempt in children and physical or sexual 
abuse has been observed by various authors (Maniglio R, 2011); the 
risk incresases in accordance with the seriousness and persistence of 
the abuse (Esposito CL et al., 2002). Parental problems of coexistence 
or the struggle for the children´s custody also increases the risk of 
attempting suicide among young people (Beautrais AL, 2000). Another 
present-day risk factor is conditioned by the new technologies, 
increasingly more accessible to everybody. Thus, the so-called cyber-
bullying in vulnerable groups of the population, such as children or 
sexual minorities, causes the appearance of suicidal attempts, turning 
this phenomenon into a problem that should be tackled urgently 
(Aboujaoude E et al., 2015). 
 
1.2.1.3.2. Old age 
In advanced age there are differences between the sexes. Old men 
usually die more frequently on their first suicide attempt (Conwell Y et 
al., 2001). Widowhood or retirement are usually factors which have a 
 more profound effect on men. A second well-known risk factor is the 
presence of a psychiatric disorder, especially depressive episodes, 
which are considered to be a major risk factor in the elderly (Turvey CL 
et al., 2002); these are present in 87% of suicides in this population 
group (Conwell Yt al., 2001). The abuse of certain substances is also 
associated with suicide in the elderly, especially men. Thus, alcoholism 
would be related to approximately 50% of consummated suicides in 
this age group (Blow FC et al., 2004). Somatic disease, especially if it 
is disabling, chronic, painful or serious, seems to be essential in the 
suicide of persons of advanced age. Thus, the risk increaes more than 
five times in patients with pain (Juurlink DN et al., 2004), sight 
impairment (Waern M et al., 2002), cancer (Waern M et al., 2002) or 
neurological disease (Waern M et al., 2002). Dependence or the 
impossibility to fend for themselves in daily activities is also relatd to a 
higher risk of suicidal behaviour (Alexopoulos GS et al., 1999). Added 
to this, the greater the concurrence of several diseases, the higher the 
risk (Harris EC et al., 1997). As a result, due to the fact that old people 
usually suffer from several pathologies at the same time, it is logical 
that this group is characterized by a higher risk. Linked to this, we also 
find the phenomenon of polypharmacy, so frequent at this age.  It 
should be pointed out that some of the most commonly prescribed 
medicines to old patients —enalapril, simvastatin, prednisone o 
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indomethacin—are associated with the apperance of depressive 
episodes (American Psychiatric Association, 2002). Additionally, a 
quarter of the patients with somatic disease suffer from depression 
(U.S. Department of Health and Human Services, 1999). Due to this, 
depression has been described as an intermediate step between 
somatic disease and the appearance of suicidal behaviour (Ratcliffe GE 
et al., 2008). Lastly, social isolation should be added to the risk factor 
of widowhood among men of advanced age. The relation between 
suicide and social isolation is clear; people who live alone have a 
higher risk of commiting a suicidal act (Heikkinen ME et al., 1995) as 
well as those with fewer friends or relatives to trust (Turvey CL et al., 
2002). Depression is a confusion factor, on the one hand it favours 
isolation and on the other hand it increases the risk of suicide by itself. 
 
1.2.1.4. Marital status 
 
A great number of studies point out that marriage is a protective 
factor (Masocco M et al., 2010). The lack of a partner (Kposowa AJ, 
2000; Wyder M et al., 2009) and the risk increase with the loss of a 
partner (Erlangsen A et al., 2004; Wyder M et al., 2009), seems to be 
more decisive among men than women. The suicide risk may be 15 
times higher in the case of widowed persons (Erlangsen A et al., 
2004). It seems that men need more time to overcome the grief, they 
 develop less close relationships outside marriage, which leads them to 
a sensation of disconnection with society without their partner, they 
express their feelings less frequently and in many cases, may find it 
more difficult to face domestic chores (Duberstein PR et al., 1998; 
Erlangsen A et al., 2004). The most delicate period is the first year 
after the loss or separation and remains high for some years 
(Duberstein PR et al., 1998). Apart from gender, the moment of the 
loss may also be a key factor. Two groups of widowed persons have 
been established: those who lose their partner the first part of their 
life, with a suicide risk which is 17 times higher in men, and those who 
suffer the loss in the second half, with a lower risk (Kreitman N, 1988). 
The risk in case of legal separation is four times as high as in the rest 
of civil statuses (Wyder M et al., 2009).  
 
A recent prospective cohort study based on an adult Japanese 
population aged 40-64 years old, assessed different lifestyles related 
to health, including marital status (Fukuchi N et al., 2013). During the 
18 years of follow-up, 106 and 40 deaths by suicide were registered in 
20,671 men (344,813 persons-years) and 21,076 women (365,524 
persons-years) respectively. Marital status was significantly associated 
with the risk of completing suicide only in the case of men, with a 
significant risk of death by suicide found among widowers and 
divorcees. Another study investigating the existing relation between 
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certain sociodemographic variables and the appearance of suicidal 
behaviours in the Iranian population observed that 75.5% of people 
committing a suicidal act were single as opposed to only 22.5 % of 
married people (Haghighi H et al., 2015). In a study conducted in 
Mexico with a sample of suicide attempters, it was found that the 
predominant marital status in men was single while it was married in 
the case of women (Fresán A et al., 2015). The results in a recent 
study with London population reveal that being single or living alone 
increases the risk of attempting suicide (Aschan L et al., 2013). 
 
1.2.1.5. Occupation and economic status 
 
Occupation is another factor that has been widely studied. In this 
section we can highlight health-related professions (Agerbo E et al., 
2007). However, lack of employment is more relevant than the type of 
employment. Unemployment has been related to the number of sui-
cides for a long time. (Durkheim E,1982; Platt S, 1984). This has been 
concluded by successive studies not only in consummated suicides 
(Heikkinen ME et al., 1997; Wong PW et al., 2008; Chang SS et al., 
2010) but also in attempted suicides (Brown GK et al., 2000; Fu Q et 
al., 2002). Different types of studies show that an unemployment situ-
ation in people causes the risk to increase between two and five times 
and this is slightly higher in men (Wong PW et al., 2008). The inci-
 dence of unemployment varies depending on age. Thus, it is more de-
termining in some age groups like those between 35-45 (Biddle L et 
al., 2008), those who have lost their job recently (Kposowa AJ, 2001), 
those who abuse alcohol (Murphy GE et al., 1992), and those patients 
with personality disorders (Heikkinen ME et al., 1997). Other factors 
connected to being jobless can also be related to suicide, namely eco-
nomic and relationship problems (Wong PW et al., 2008). Besides, 
psychological and psychopathological problems may make it difficult to 
find and maintain a job (Fu Q et al., 2002). It is also posible that the 
consumption of alcohol (Pirkola SP et al., 2000) or depressive episodes 
(Meltzer H et al., 2010) after losing a job might lead to suicidal behav-
iour.  
 
1.2.1.6. Religious beliefs 
 
Religious beliefs and their importance in people’s lives have an influ-
ence on the inclination towards suicide (American Psychiatric Associa-
tion, 2004). People with strong religious convictions who consider sui-
cide as morally objectionable or whose religious beliefs give meaning 
to their lives seem to have more difficulty in taking the step from 
death thoughts to suicidal action (Hovey JD, 1999; Dervic K et al., 
2006). Notwithstanding the above, suicide rate is higher among 
Protestants, followed by Jews, Catholics and Muslims in the last place 
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(Lester D, 2006). However, we must be cautious when dealing with da-
ta collected in countries where there might be a bias in the information 
due to cultural and religious influence or in which suicide is socially 
condemned or with a  criminal conviction (Kelleher MJ et al., 1998). In 
a study in the United States aimed at investigating the influence of so-
cioeconomic factors, the number of psychiatric disorders and religious-
ness over suicidal ideation, it was observed that Afro-American men 
with multiple psychiatric disorders and not particularly religious 
showed a high risk of suicidal ideation (Assari S, 2015). 
 
1.2.1.7. Social support 
 
Social integration has been the cornerstone in the social theory of 
suicide (Durkheim, E, 1982). It has been considered that the presence 
of an adequate social network represents a protective factor (Turvey 
CL et al., 2002) and social isolation, on the contrary, would entail a 
higher risk of suicidal behaviour at any age (Pompili M et al., 2008). 
However, it seems that isolation has more influence on suicide than on 
the suicide attempts, probably because the degree of isolation in the 
consummated suicide is higher (Saiz PA et al., 2011). Isolation can be 
related to diffiuculty in communicating with other people and 
establishing a love relationship, both being suicide attempt risk 
factors. 
 
 1.2.1.8. Previous suicidal behaviour 
 
The most reliable indicator of suicide risk is having attempted suicide 
previously (Blumenthal SJ, 1988). 42% of men and 45% of women, 
who try to commit suicide, have already attempted it before. 
According to a study, 16% of men and 17% of women who have tried 
to commit suicide will have a suicide attempt again in the following 
year (Schmidtke A et al., 1996). Many studies point to the same idea, 
that previous suicide attempts are the best indicator of the probability 
of a future consummated suicide (Christiansen E et al., 2007; Haukka 
J et al., 2008; Ruengorn C et al., 2012). Thus, attempters are 40 times 
more likely to die by suicide (Harris EC et al., 1997). Other authors, 
however, warn about the limitation of that background. The reason is 
that an important amount of consummated suicides are completed in 
the first attempt, especially among men (62% against 38% for 
women) (Isometsä ET, 2001), while 82% of those who tried to commit 
suicide and did not succeed, completed it on a second attempt by 
shifting to a more lethal method (Isometsä ET, 2001).  
In a systematic revision of 14 population groups totalling 21,385 
individuals, it was estimated that those with suicidal background have 
almost 25 times more probabilities of dying from suicide than the 
general population (Neeleman J, 2001). Based on several prospective 
studies, it can be stated that between 1% and 6% of those who are 
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admitted in hospital for a suicide attempt will die from suicide in the 
following year. The risk is higher in old people or with several previous 
attempts (Suokas J et al., 2001; Silverman MM, 2006). Therefore, to 
avoid the repetition of those attempts, it is paramount to assess 
correctly the people who arrive at the health services after having 
attempted suicide. (Kapur N et al., 2008). 
 
1.2.1.9. Geographic distribution 
 
Suicide rate varies greatly across countries. On the whole, Latin 
American countries have a lower suicide rate than the USA, and 
countries in the South of Europe lower as well than those in the North 
and East (World Health Organization, 1998). Urban areas register a 
greater occurrence of suicide and suicide attempts. In fact, the 
number of attempted and completed suicides increases in accordance 
with the greater number of inhabitants in cities. It is in areas with an 
accumulation of ageing population or citizens on lower incomes where 
most cases are recorded. However, in residential areas with people 
with a higher standard of living, suicide rate diminishes (Lastra I et al., 
1998). 
1.2.1.10. Season, day of the week and time of day. 
 
The majority of statistical studies available coincide in the fact that 
in the winter month’s suicide occurrence decreases. The said 
 occurrence gradually increases as spring comes, with surges in the 
months of May and June (Buda M et al., 1990).  
 
1.2.2. Modifiable risk factors  
1.2.2.1. Mental disorder 
 
Suicide behaviour is, in most cases, a complication of a psychiatric 
disorder. More than 90% of suicide victims suffer a psychiatric disorder 
(Isometsä ET, 2001). Among psychiatric patients there is a greater 
occurrence, often more than 30% than among other types of patients 
(Muehlenkamp JJ et al., 2011; Glenn CR et al., 2013). In the meta-
analysis published by Arsenault-Lapierre (Arsenault-Lapierre G et al., 
2004), which included 27 studies with a total of 3,275 suicides, 87.3% 
of the patients had been diagnosed with a mental illness. In another 
epidemiological study based on a sample of 894 youths aged 10-30 
years old who had committed suicide, 88.6% had at least one 
diagnosis of mental disorder, with affective disorders being the most 
frequent (42.1%), followed by substance abuse (40.8%) (Fleischmann 
A et al., 2005). It is worth noting that suicide risk is higher in the early 
stages of the illness (Harris EC et al., 1997); a higher risk has been 
identified in the first six months following discharge after hospital 
admission (King EA et al., 2001; Hawton K et al., 2009). Some of the 
most common previous psychiatric disorders are major depression 
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(Möller HJ, 2003), the most frequent, followed by alcohol and illegal 
drugs intake (Vijayakumar L y et al., 2011). 
 
According to a different study, major depression increases 20 times 
the risk of suicide (Harris EC et al., 1997), bipolar disorder 15 times 
and dysthymia 12 times (Coryell W et al., 2005). The first three 
months after a major depression episode carry a higher suicide risk 
(Ruengorn C et al., 2012). The risk is especially high at the start or 
end of the episode. In the state phase, psychomotor retardation and 
inhibition hinder execution (Hawton K et al., 2005). It has been 
estimated that 15% of patients with a major depressive disorder will 
commit suicide (Guze SB et al., 1970). In a meta-analysis based on 41 
studies and a total sample of 31,159 individuals, it was observed that 
the number of suicides in patients with a depressive disorder doubles 
that of suicides in hospitalizations for other reasons (8.6% against 
4%)  (Bostwick JM et al., 2000).  
In a different study it was observed that the persons who were more 
likely to have resorted to health services for having death ideas or 
having attempted suicide turned out to be white women, white people, 
not hispanic, people with a poorer health condition in general, those 
with a more serious clinical condition and in particular those who had 
or had had a major depression diagnosis (Stanley IH et al., 2015). 
 
 1.2.2.2. Schizophrenia 
 
A prevalence of consummated suicide of up to 10% has been 
reported in schizophrenic patients (Hawton K et al, 2005). In a 
systematic revision of 61 studies, with a total sample of 48,176 
individuals, a prevalence of suicide of 4.9% among schizophrenic 
patients was estimated (Palmer BA et al., 2005); these patients have 
shown a suicide risk 8.5 times higher than the general population 
(Harris EC et al., 1997). Schizophrenic patients may also add other 
risk factors which should be taken into consideration, such as being 
male, of white race, having depression, being single, unemployed, 
living alone or being socially isolated. Factors with bad prognosis in 
schizophrenia like being young, having numerous relapses, an elevated 
number of psychiatric admissions, socio-labour or sexual deterioration 
and poor therapeutic adherence also increase the risk of suicide in 
those patients (Hawton K et al, 2005). 
  
1.2.2.3. Anxiety disorder  
 
Anxiety is often connected with death ideas and the appearance of 
suicide attempts (Allan NP et al., 2015). Almost 20% of patients with a 
disorder due to anguish or a social phobia attempts suicide at least 
once in their lives and if this disorder is compounded with depression, 
the likelihood of consummating suicide increases (Warshaw MG et al., 
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2000; Khan A et al., 2002).  
 
According to Harris and Barraclough (Harris EC et al., 1997), the risk 
of suicide increases between 6 and 10 times depending on the 
different anxiety disorders: generalized anxiety disorder, obsessive 
compulsive disorder or panic disorder. However, other studies have not 
identified a significant increase of suicide risk in the context of an 
anxiety disorder, without the presence of depressive symptoms 
(Beautrais AL, 2000). The relationship between suicide attempts and 
being prone to anxiety is coherent with theories which state that those 
attempts are the consequence of the inability to face unbearable 
anguish (Allan NP et al., 2015).  Anxiety disorders and personality 
disorders are also associated with a rise in the risk of suicidal 
behaviour; especially the borderline personality disorder which is the 
most commonly associated one in the case of adolescents and young 
adults (Muehlenkamp JJ et al., 2011; Glenn CR et al., 2013). 
 
1.2.2.4. Substance abuse 
 
The consumption of toxic substances has been the focus of attention 
of authorities and researchers. It is known that disorders caused by 
the abuse of substances, especially alcohol, have been frequently 
related with suicide, both as a base risk factor and as a suicide trigger. 
(Allan NP et al.,2015). Up to 15% of alcoholic patients try to commit 
 suicide and alcohol abuse is present in 25-50% of all suicides (Conner 
KR et al., 2004). Alcohol consumption may also be associated with 
organic illnesses, mood disorders, personality disorders or impulse 
control disorders, which additionally implies a suicide risk rise 
(Gorwood P, 2001; Cherpitel CJ et al., 2004). Apart from alcohol, 
another toxic but legal substance is tobacco, whose influence on 
suicidal behaviour has been described in numerous studies. It has 
been observed that the risk of attempting suicide is greater among 
smokers (Yaworski D et al., 2011; Berlin I et al., 2015). It also appears 
that this risk would be greater in psychiatric patients who smoke and 
are hospitalized (Hooman S et al., 2013). Some studies have 
evaluated whether this risk is modified by patient gender, but the 
findings reveal that tobacco addiction is associated with the existence 
of an increased suicidal ideation (Scherrer JF et al., 2012). On the 
other hand, the majority of authors agree that the consumption of 
illegal drugs (opioids, cocaine, cannabis, etc.) may also increase the 
risk of suicide attempt, especially in the case of poly-consumption, 
where the risk may increase up to 20 times with respect to the base 
reference level (Harris EC et al., 1997). When analizing illegal 
substance intake in patients who had injured themselves, some 
authors found that drug consumption in young women was associated 
with higher scores in the suicide intent scale (Haw CM et al., 2011). In 
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a study carried out in Scotland, the use of illegal drugs, with or 
without the consumption of cannabis, was significantly associated with 
a greater likelihood of depression, suicide thoughts and suicide 
attempts (Rasic D et al., 2013). For other authors, the occasional use 
of cannabis over other illicit drugs would be indeed associated with an 
increased probability of attempting suicide (Artenie AA et al., 2015).  
 
Other studies suggest that the use of other drugs such as inhalants 
or cocaine are particularly associated with suicidal behaviour and 
notably increase the risk, above all, when consumption takes place in 
persons with psychiatric disorders (Vijayakumar L et al., 2011). 
Therefore, most authors agree that the use and dependence on 
alcohol, tobacco and illegal drugs is related with suicidal behaviour 
(Miller M et al., 2011).  
 
On the other hand, it is well-known that the combination of 
depressive disorders and addictions is especially deleterious (Wilcox 
HC et al., 2004). Depressive symptoms may be the consequence of a 
psychiatric disorder or the result of the toxic effects of alcohol, hepatic 
alteration and malnutrition, as well as organic brain syndromes 
secondary to head trauma. Another usual problem among addiction 
substance users is low adherence to treatments. If this is compounded 
with an elevated frequency of additional psychiatric disorders, mainly 
 of the depressive scope, the probability of a suicide attempt increases 
greatly (Conner KR et al., 2004). 
 
1.2.2.5 Personality disorders 
 
It is essential to consider personality traits as possible goals to 
prevent suicide (Menon V et al., 2015). These disorders play an 
important role as they can influence suicide behaviour in a number of 
ways. They predispose to more serious disorders such as depression 
and alcoholism, which, in turn, involve relationship and social 
adaptation problems (Pompili M et al., 2005). It has been stated that 
the majority of patients with personality disorders who take their lives 
also meet the criteria for other serious mental illnesses such as 
depression, substance abuse or both, and this association is still more 
frequent in cluster B personality disorders (Isometsä ET, 2001). 
Borderline personality disorder (BPD) is common among patients with 
non-oncological chronic pain, often more prone to the abuse of opioid 
analsegics and the prevalence of suicide is high in these patients 
(Campbell G et al., 2015). In the Harris and Barraclough revision 
mentioned above, personality disorders increase up to six times the 
risk of suicide (Harris EC et al., 1997). Despair, neuroticism and 
extroversion were the most clearly connected features (Brezo J et al., 
2006); others, like aggressiveness, impulsivity, irritability, hostility or 
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anxiety have demonstrated less conclusive associations.  
 
1.2.2.6. Other mental disorders 
 
There are other mental disorders that also increase suicide risk. 
People with attention deficit disorder have a higher probability of 
consummating suicide, above all men suffering from depression and 
associated behaviour disorders (James A et al., 2004), also those with 
eating disorders (Pompili M et al., 2006), in particular those suffering 
from anorexia and bulimia nervosa with depressive symptoms and/or 
substance abuse.  
An adjustment disorder can also increase the risk of committing a 
suicide attempt or consumating suicide. In those patients, a suicide 
risk increase of up to 14 times over the risk of the general population 
has been observed (Harris EC et al., 1997). Among previous life events 
the following can be highlighted: processes related to age (like the 
moment when the offspring marry or leave home, retirement, the 
need for home assistance, moving into an old people´s home, etc.) 
work, love relationship and health problems and disease or death of a 
relative (Conner KR et al., 2001). 
Few studies have examined in a prospective way if depression 
symptoms and other risk factors are associated with a higher risk of 
death by suicide in those populations without a psychiatric or suicide 
 background. In a recent study, it was prospectively studied whether 
the depression symptoms assessed by the Beck Depression Inventory 
(BDI) are associated with a higher risk of death by suicide and 
whether depression symptoms and other risk factors are independent 
suicide predictors in the general population (Yi SW et al., 2015). The 
study concluded that depression symptoms in middle-aged men are a 
strong independent predictor for suicide attempt and the same 
happens with other factors like having a poor health state, a low 
educational level or a high consumption of alcohol. 
 
1.2.2.7. Physical Health 
 
Illnesses involving disability or pain, chronic and intense, are well-
known suicide risk factors (Stenager EN et al., 2000). Chronic or 
disabling illnesses such as hypertension, diabetes, or migraine and 
some respiratory and neurological alterations also increase the risk of 
developing suicidal behaviour (Scott KM et al., 2010). Besides, a 
higher risk has been detected in patients diagnosed with cancer, HIV, 
Huntington disease, multiple sclerosis, renal insufficiency, spinal cord 
injury or lupus, among others (Pompili M et al., 2005). According to 
these studies, the appearance of depression symptoms may be a 
decisive factor in this type of patient (Tang NK Y et al., 2006). High 
intensity long-lasting chronic pain associated with insomnia is also an 
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important risk factor for suicide (Cheatle MD, 2011). A recent 
retrospective study investigated the influence of psychiatric 
comorbidity in the perception of pain (Ciaramella A et al., 2015); both 
agoraphobia and depression and other psychiatric disorders were 
associated with an overall increase of pain intensity. 
 
1.2.2.8. Psychological dimensions 
 
Impulsivity and aggressiveness are those dimensions most closely 
associated with suicidal behaviour in the majority of proposed models 
(Mann JJ et al., 1999; Conner KR et al., 2003). This relationship has 
been confirmed by several studies (Joiner TE et al., 2005; Zouk H et 
al., 2006). It seems clear that the most aggressive individuals are 
more likely to commit acts related to suicide, homicide and violence in 
general (Conner KR et al., 2001); those deceased by suicide therefore, 
display aggressive and violent conduct with more frequency than those 
deceased by other causes like traffic accidents. This relationship is 
more evident in young patients or adolescents, as well as those 
serving time in prison (Conner KR et al., 2003). The authors of the 
said studies highlight the importance of analysing personality traits in 
order to determine suicide risk accurately. Other psychological 
dimensions associated with suicidal behaviour are aggressiveness 
independently from impulsivity, hopelessness, dichotomous thinking, 
 cognitive rigidity and difficulty in problem solving. Aggressiveness, 
which is not always associated with impulsivity (Herpertz S et al., 
1995), has been associated with violent suicide (Berglund M et al., 
1998), with suicides in young men (Prigerson HG et al., 1999), with 
suicide attempts among the general population (Doihara C et al., 
2008) and in psychiatric population (Mann JJ et al., 1999). 
Hopelessness, as an expression of the limitation of success 
expectations (Melges FT et al., 1969), has been connected with 
suicidal behaviour in psychiatric pathologies (Kamath P et al., 2007), 
especially in schizophrenia (Berlin I et al., 2015), and somatic 
pathologies (Pompili M et al., 2007). As a result, these psychological 
dimensions favour hopelessness and are associated, in an independent 
way, with the appearance of suicidal behaviour.  
 
1.3. Protective factors 
 
The most common protective factors can be divided in two. Those 
particular to the individual and those coming from the environment 
(Center for Disease Control and Prevention, 2010). Among the first we 
can include individual attitudes, values and norms against suicide, like 
the value given to life itself. Besides, social skills, anger management 
and the ability for problem solving favour the decision not to commit 
suicide. Other characteristics connected with protection are the care 
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and search for mental and somatic health, religious beliefs which 
oppose suicide, fear of pain and risky actions, the presence of hope 
and optimism, self-control of impulsivity, self-esteem and adequate 
strategies for coping and high resilience. In a study it has been 
observed that mortality by suicide was inversely associated with the 
body mass index. In this sense, whereas an elevated body mass index 
is associated with a higher risk of depression and anxiety, the 
accumulated evidence indicates that it is a protective factor for suicide 
(Bjørngaard JH et al., 2015). The existence of an adequate social and 
family network with bonds towards their members, social participation, 
accessibility to healthcare services, a stable atmosphere and 
restrictions to the purchase of weapons or potentially lethal medication 
are some of the main environmental factors which have to be taken 
into consideration as protective factors (Wasserman D et al., 2012).  
 
1.4. Summary 
 
Suicidal behaviour is one of the greatest issues of public health 
these days, both in terms of economic costs and social, healthcare and 
personal ones (Martín YM et al., 2011). The extent of the problem is 
not only defined by the mortality caused by consummated suicide. The 
influence of the suicide thoughts, the suicide attempt and the 
consequences over the quality of life of the population is also 
 important. The WHO statistics pinpoint suicide as one of the main 
causes of lifetime years lost by illness. In spite of the differences 
among countries connected with availability or social acceptance, it 
seems obvious that men tend to opt for more violent methods and 
women for less aggressive ones  (Sarró B et al., 1991). This is a key 
factor to understand why men consummate more suicides than 
women. In Spain, the most common methods are precipitation and 
hanging (Arranz Estévez FJ, 1997). Among suicide attempts the most 
common system is intoxication with 64% of men and 80% of women 
opting for this method in a Europe-wide study. (Schmidtke A et 
al.1996). It is necessary to take into account the associated risk 
factors in order to prevent suicidal behaviour. As we have seen, non-
modifiable risk factors like a family or personal background of suicidal 
behaviour, the gender and age of the patient, are accompanied by 
social demographic variables which are hardly modifiable like marital 
status, work situation, religious beliefs and social support. We also 
know that almost every individual who consummates suicide and a 
high percentage of those who attempt it or think about it, suffer some 
type of associated mental disorder.  
Although suicide risk is associated with the number of risk factors 
present, a wider model of diathesis-stress has been proposed, as a 
useful tool to understand the risk of suicidal behaviour (Mann JJ, 2003) 
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(Figure 3). The model includes two interrelated ingredients: those 
characteristics inherent to the person (genetics, substance abuse, 
personality and impulsivity) and the characteristics of the triggering or 
precipitating factors (acute psychiatric illness or adverse life events). 
The combination of both components would be more important in 
order to establish the risk of suicidal behaviour than a mere 
accumulation of risk factors. This highlights the importance of a 
correct assessment of patients with suicide risk which comprises both 
population risk factors and risk factors related to the mental illness 
itself. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3 Stress-diathesis model for suicidal behaviour (Adapted from 
Mann, 2003) 
 
 
*Source: Own elaboration 
 
1.5. Medication and suicidal behaviour  
 
Nowadays, when the symptoms and signs of mental illness are 
sufficient to require the use of medication, it is considered that there is 
no reason to deprive patients of the potential benefits of 
pharmacological treatments (Hawton K et al, 2004). But however 
paradoxical it may seem, some of the drugs used in the treatment of 
psychiatric illness and more specifically in the treatment of suicidal 
behaviour have sometimes been associated with the appearance of 
that same conduct.  
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Thus it turns out that the possible inducement to suicide by certain 
drugs which seek precisely its prevention is a cause for concern, 
controversy and intense discussion. 
 
It is admitted that serotonin and some of its receptors are altered in 
the case of the suicidal and depressed patient. For this reason, drugs 
that inhibit serotonin reuptake (SSRIs) are often used to treat patients 
with depression symptoms associated with suicidal behaviour. Every 
patient with depression or suicide ideas has to be hospitalized, receive 
adequate treatment and be under constant supervision. However, 
although the right medication reduces in the short and long term the 
morbidity and mortality of suicide, suicidal behaviour is a complex 
problem which goes beyond the effect of antidepressants and other 
medication (Sakinofsky I, 2007; Rihmer Z et al., 2015). 
 
A review of psychodrugs and suicide has been carried out recently 
(Yerevanian BI et al., 2013) including all the articles published on this 
area from January 1960 to January 2013 and using relevant key words 
to identify the studies. The updated information of the FDA was also 
consulted. The available studies used different methods which 
hindered the interpretation of the findings. In general, the majority of 
studies suggest that antidepressants may increase the risk of suicide 
in bipolar disorder and other disorders of the depressive spectrum. 
 There is no evidence that antiepileptic drugs increase the risk of 
suicide. Little is known about the effect of antipsychotics as well as the 
effect of anxiolytic and hypnotic drugs over suicidal behaviour. 
 
1.5.1. Antidepressants 
 
Antidepressants have been used profusely in the treatment of 
depression on the basis of the known results of clinical studies. 
Depression, as it has been commented before, is the psychiatric 
disorder which is associated with the highest risk of suicide. Also, the 
lethality of the suicide attempts is connected with the seriousness and 
duration of the depression. It is accepted that adequate treatment of 
depression reduces attempts and death by suicide. Among the patients 
with major depression disorder, the occurrence of suicide attempts 
varies remarkably depending on the seriousness of depression, with a 
higher incidence during acute episodes of major depression (Holma KM 
et al., 2010). Consequently, the serotonergic hypothesis of suicide 
together with the apparently low profile of toxicity that they possess 
provided SSRI antidepressants with a major role in the 
pharmacological treatment of  suicidal behaviour in principle. This 
group of drugs includes fluoxetine, fluvoxamine, paroxetine, sertraline, 
venlafaxine and citalopram, among others.  
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For years after these drugs were first marketed, these drugs were 
welcomed warmly. Some studies described a decrease of suicidal 
behaviour through the use of SSRIs, which would seem to support the 
effectiveness of these drugs. (Martínez JC et al., 2007). An example of 
this is the prospective study developed in the USA where the effects of 
fluoxetine in patients with depression were evaluated (Milane MS et al., 
2006); according to the results of this study, the period 1988-2002 
saw a decrease of suicide in patients taking this drug. Another study 
conducted in Sweden concluded that the enormous increase in the use 
of SSRIs in the 90s was accompanied by a significant decrease in the 
number of suicides with respect to previous years to their introduction 
in the market (Isacsson G et al., 1997). Nevertheless, the relationship 
between some antidepressants and suicide risk increase has been 
controversial. From the year 1990 the first warnings appeared about 
the relationship between suicidal behaviour and the use of SSRIs in 
children and adolescents (Bailly D, 2006); these behaviours included 
excitation, motor restlessness, social disinhibition and self-destructive 
behaviour. However, clinical tests provided little data that could help to 
confirm these initial observations. Thus, in March 2004, the FDA 
suggested restricting and monitoring the use of some types of SSRIs 
in the face of the possibility of depressive symptoms and suicide ideas 
worsening. Finally, in October 2004, after assessing 26 studies, the 
 FDA issued a warning (black warning) in the packets of these drugs 
aimed at the prevention of these risks in under-18s (Brent DA et al., 
2004). Later, the original warning was modified and the FDA specified 
that the use of SSRIs may produce and increase of suicide ideas and 
suicidal behaviour but not consummated suicide. In June of that year, 
the body made the announcement that the risk of suicide attempts in 
adults treated with SSRIs would also be increased (Brent DA et al., 
2004). Following that, the warning was extended to persons over 18 
years old, with the labelling in the packets indicating that depression 
itself was associated with a higher risk of suicide at any age. Besides, 
the agency stated that patients being treated with antidepressants and 
especially those being treated for major depression should be under 
close surveillance given the probable worsening and appearance of 
suicidal thoughts or behaviour through the use of this medication 
(FDA, 2004). The mechanisms responsible for the risk increase in 
children and adolescents could be various. It might be connected with 
the intrinsic action of the drug itself, have something to do with 
accidental overdoses, inefficacy of the treatment and consequently 
with the persistence of the depressive symptoms and finally it might 
be associated with the initial activation that these drugs produce and 
would take the patient from the stage of suicide ideation to the suicide 
act (Healy D et al.,1999). As the warnings were originally targeted at 
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children and adolescents, there was a decrease of drug prescription for 
this group of patients (Olfson M et al., 2008). However, the clinical and 
real public health consequences of these steps are unknown (Kurian BT 
et al., 2007). As a result, even though SSRIs continued as a first line 
pharmacological treatment for this group of patients, they were 
reserved to those cases where no psychotherapy was available or this 
was insufficient (Sharp SC et al., 2006).  
 
Nevertheless, and despite the warnings, some researchers did not 
find an increase of the suicide attempt risk in SSRI users (Helgason T 
et al., 2004; Zahl PH et al., 2010). Thus, controlled studies including 
ample samples of patients did not evidence a greater risk of suicidal 
behaviour comparing the placebo with some specific SSRIs (Sharp SC 
et al., 2006; Baldwin DS et al., 2007; Tauscher-Wisniewski S et al., 
2007). It has been argued that SSRIs have a protective action in 
adults and that there is no evidence to support its connection with 
suicide (Gibbons RD et al., 2007). As regards children and adolescents, 
even though some epidemiological data suggested that SSRIs could 
increase this risk, other epidemiological data showed that mortality by 
suicide in children and adolescents might have decreased since their 
introduction (Bailly D, 2006). Although in the case of the most 
vulnerable patients the risk of attempting suicide might increase in the 
 first days of antidepressant treatment, no evidence was found that the 
risk was greater with SSRIs than with other antidepressants or non-
pharmacological treatments (Hegerl U, 2007). 
 
Other studies have found approximately twice as much relative 
suicide risk with antidepressants than with patients taking a placebo 
(Healy D et al., 2005); paradoxical suicide ideas have been observed 
associated with desimipramine (Damluji NF et al., 1988), even with 
maprotiline (Rouillon F et al., 1989) and amitriptiline (Soloff PH et al., 
1987). In patients taking venlafaxine, a greater risk of attempting 
suicide was observed than with the use of other antidepressants 
(Tiihonen J et al., 2006). A different study compared the presence or 
absence of SSRIs in the plasma of patients who had attempted suicide, 
regardless of whether this had been consummated or not (Fazel S et 
al., 2007); among more than 14,000 cases studied, around 13% had 
detectable plasma levels of SSRIs, not finding differences by age or 
gender and with a smaller use of violent methods. In a similar study 
with very young patients, rests of imipramine or fluoxetine, but not 
other antidepressants, including paroxetine, were only found in around 
6% of the patients (Leon AC et al., 2007). It is known that even 
though antidepressant drugs are the cornerstone of treating patients 
with depression, they may also carry serious risks (Teicher MH et al., 
1993). In recent study 238,963 patients aged 20-64 were analysed for 
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a period of 12 years with an initial diagnosis of depression. During 
follow-up, 87.7% of patients (n = 209,476) were prescribed one or 
more antidepressants. The duration median of the treatment was 221 
days (interquartile range 79-590 days). In the first five years of follow-
up, 198 cases of consummated suicide and 5,243 cases of attempted 
suicide or self-injury took place. The authors did not find a significant 
difference between the users of tricyclic antidepressants and SSRIs as 
regards the risk to commit consummated suicide. (OR=0.84; CI 
95%=0.47-1.5) but the risk of consummated suicide risk increased 
significantly in the periods of treatment with other antidepressants 
(OR=2.64; CI 95%=1.74-3.99). The risk ratio for consummated 
suicide increased significantly for mirtazapine in comparison with 
citalopram (OR=3.7; CI 95%=2-6.84). The absolute suicide risks in a 
year ranged from 0.02% for amitriptiline to 0.19% for mirtazapine. No 
greater risk of attempting suicide or self-injury was found with tricyclic 
antidepressants (RR= 0.96; CI 95%=0.87-1.08) in comparison with 
selective serotonin reuptake inhibitors (SSRIs). The adjusted risk of 
suicide attempt or self-injury increased significantly for three of the 
most prescribed drugs in comparison with citalopram: venlafaxine 
(OR=1.85; CI 95%=1.61-2.13), trazodone (OR=1.73; CI 95%=1.26-
2.37) y mirtazapine (OR=1.70; CI 95%=1.44-2.02), and was reduced 
significantly in the case of amitriptiline (OR=0.71; CI 95%=0.59-
 0.85). The risk was greater in the first 28 days after initiating 
treatment and remained the same after suspending it (Coupland C et 
al., 2015). Another recent study centred around describing the 
appearance of suicide ideas and suicide attempts in a group of 
adolescents who were hospitalized due to depression and treated with 
SSRIs for a period of three months after discharge (Ghaziuddin N et 
al., 2014); the risk of appearance of suicide ideas or suicide attempts 
was associated with the intake of an antipsychotic drug in combination 
with an SSRI. Another study compared the proportion of suicide 
attempts during treatment with antidepressants with the previous 
proportion to the commencement of the treatment (Termorshuizen F et 
al., 2015). In this study, an increased risk of suicide attempt was 
found among those over 25 years old in the month prior to the 
commencement of the pharmacological treatment as well as an 
increased risk in the first month of treatment and a tendency for risk 
to diminish in later months with antidepressants, although in none of 
the cases were the results statistically significant. Besides, it was 
observed that the appearnce of events connected with suicide was 
greater in persons over 40 years old and in the first month of 
treatment.  
 
To this day, there is no clear explanation of why SSRIs might 
increase this risk. In any case, it seems that these effects are not only 
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unique to children and adolescents but they have also been observed 
in adults (Bailly D, 2006). Different mechanisms have been proposed 
to explain this adverse effect, namely, encouraging patients with 
depression to act in the context of a preexistent suicide idea to the 
start of the treatment, paradoxical worsening of depression, inducing 
akathisia, aggressiveness and autolysis impulses secondary to the 
discomfort that it provokes, inducing panic attacks, swerving from a 
depressive stage to a maniac or mixed stage, with the corresponding 
activation of impulses and scarce restraint of conduct, causing serious 
insomnia or interference in the sleep patterns with worsening of the 
depressive clinical state, heightened psychopathological alterations 
such as obsessive behaviour and lack of control of impulses, as well as 
other neurological alterations (Teicher MH et al., 1993). 
 
Another vulnerable group is that of the elderly. This group requires 
careful anamnesis given the high frequency of depression and the 
elevated risk of suicide among them (Fischer LR et al., 2003). The 
exploration of death ideas during treatment with SSRIs in the elderly is 
compulsory. It must be noted that suicide thoughts might occur or 
increase in the first days of any antidepressant treatment (Healy D et 
al., 1999). Besides, we are aware that suicide ideas in the early stages 
of pharmacological treatment are frequently associated with the 
 worsening of the symptoms (Perlis RH et al., 2007). Likewise, in some 
patients the suicide risk might increase in the first days of any 
treatment, not only pharmacological, but also theurapeutic. This 
mechanism is common to any antidepressant and is greater in the first 
stage of treatment, when the mechanisms start to have effects, 
therefore, explicit warnings and monitoring the early stages of 
treatment might reduce to a great extent these risks (Healy D et al., 
1999). It is therefore advisable to monitor the treatment closely (Kölch 
M et al., 2007) and consider an alternative treatment in the case that 
other symptoms appear, such as restlessness (Andrade C et al., 2006). 
Pharmacological treatment must be restricted to those cases where 
psychotherapy is not effective (Bhatia SK et al., 2007), with the 
combined use of SSRIs and psychotherapy being an alternative 
(Hughes CW et al., 2007). It is paramount to remember that suicide 
attempts are more frequent in the months before and after the start of 
the treatment, regardless of the type of drug used or the 
psychotherapy (Simon GE et al., 2007; Schneeweiss S et al., 2010). 
SSRIs must be used selectively and carefully with children and 
adolescents, avoiding their routine prescription; their use must be 
reserved to serious cases or when psychotherapy itself is not sufficient 
(Bailly D, 2006). Besides, when dealing with children and adolescents, 
only psychiatrists should prescribe and supervise the treatment with 
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SSRIs (Cohen D, 2007). Choice of antidepressant will depend on 
gender, age, abuse or dependence on drugs and the number of 
medicines prescribed and clinical response (Kim HM et al., 2015). Close 
monitoring of the treatment must be made in order to detect the 
appearance of adverse effects, as is the case with patients of advanced 
age. Suicide prevention population schemes tend to centre on early 
diagnosis and the treatment of major depression and the factors 
associated with risk, above all in the case of individuals being treated 
with SSRIs and the most vulnerable groups (Bernal M et al., 2007). 
 
In any case, study results do not seem conclusive: it is not possible 
to put suicide risk only down to antidepressants since depression itself 
typically involves suicide ideas and suicide risk (Martínez JC et al., 
2007). It is currently accepted that there is an increase in the 
appearance of suicidal behaviour in children treated with SSRIs 
connected with an increase in the appearance of impulsive conduct in 
the first few weeks of treatment. As a result, the use of this type of 
medication remains controversial (Sakinofsky I, 2007). Untreated 
depression is associated with suicide risk and additionally there are 
negative impacts on the normal life of patients. However, available 
studies do not make it clear whether SSRIs would modify this risk in a 
clinically significant way (Hetrick S et al., 2007). The majority of 
 studies carried out had numerous limitations; there are remarkable 
differences between patients seeing a professional and those 
participating in studies so it is difficult to draw definitive conclusions. 
The studies conducted up to this day only provide limited data; clinical 
tests, while providing useful data about the efficacy of the drug, 
present limitations in order to identify certain adverse effects (Bailly D, 
2006). However, these studies have been useful to guide future 
research (Sharp SC et al., 2006; Jiménez-Arriero MA et al., 2007). For 
all of the above, the relationship between antidepressants and suicide 
tendencies still remains today a topic of uncertainty and controversy 
(Olmer A et al., 2012).  
 
1.5.2. Antiepileptics 
 
Antiepileptic drugs are a heterogenous group of drugs, with different 
action mechanisms, that share a depressive action over the Central 
Nervous System. They take effect, among others, on the gabaergic 
receptors (Czapiński P et al., 2005).  Although they constitute the 
main treatment for epilepsy, they are also used for mania, migraine 
and neuropathic pain; they also have anxiolytic action, both clinically 
and experimentally (Elliot EE et al., 2000; Ashton H et al., 2003; Stahl 
SM, 2004). 
 
In different studies the efficacy of carbamazepine, la fenitoine and 
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valproic acid has been observed in the treatment of impulsivity, in the 
reduction of the frequency and intensity of behaviour alterations and in 
the treatment of anguish and hostility (Donovan SJ et al., 2000). Thus, 
apart from diminishing the risk of suicide associated with epilepsy, 
antiepileptics could be efficient in the reduction of impulsivity and 
associated suicidal conduct (Stein DJ et al., 1995). In this sense, the 
different antiepileptics have been analysed; lamotrigine proved 
effective — in a number of cases of personality disorder— in the 
reduction of impulsive symptoms and suicidal behaviour (Pinto OC et 
al., 1998). Other antiepileptics like gabapentine or topiramate have 
proved to be effective against impulsiveness in different psychiatric 
disorders as in the case of binge shopping or eating (Halmi KA, 2013; 
Ye L et al., 2014). 
 
However, in spite of these properties, apparently beneficial, in the 
year 2008 the FDA issued a warning with respect to the probable risk 
of appearance of suicidal behaviour associated with the use of various 
antiepileptic drugs, among which lamotrigine was present (U.S. Food 
and Drug Administration, 2008). Later, in order to confirm the warning 
issued by the FDA, a cohort study was conducted in patients who had 
started anticonvulsant treatment (Patorno E et al., 2010); the study 
identified 26 consummated suicides, 801 suicide attempts and 41 
 violent deaths out of 297,620 new cases of treatment with 
anticonvulsant medication (global average tracking of 60 days). The 
incidence of the combined result of consummated suicides, suicide 
attempts and violent deaths for the antiepileptics used in at least 100 
episodes of treatment ranged from 6.2 out of 1,000 persons per year 
for primidone to 34.3 out of 1,000 persons per year for oxcarbazepine. 
When compared with topiramate, the risk of suicide acts was greater 
for gabapentina (OR=1.42; CI 95%=1.1-1.8), lamotrigine (OR=1.8; 
CI 95%=1.4-2.4), oxcarbazepine (OR=2.1; CI 95%= 1.5-2.8), 
tiagabine (OR=2.4; CI 95%=1.6-3.5), and valproate (OR=1.6; CI 
95%=1.2-2.2). Consequently, in this study it was observed that the 
use of gabapentine, lamotrigine, oxcarbazepine and tiagabine, in 
comparison with topiramate or carbamazepine, was associated with a 
greater risk of committing suicide acts or suffer violent deaths. In this 
same study, alterations in the mood and behaviour changes associated 
with the intake of antiepileptics were identified. Other observations on 
the contrary suggest that valproate and carbamacepine may be 
protectors or neutral whereas only topiramate and lamotrigine would 
have a profile related to the idea of death (Fountoulakis KN et al., 
2012). The relationship between the consumption of antiepileptic 
drugs and the appearance of suicide behaviour has also been studied, 
using the data of a representative sample of the general population of 
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the United Kingdom (Arana A et al., 2010); in a cohort of 5,130,795 
patients the estimated incidence of episodes related with suicide for 
every  100,000 persons/year was 15.0 among patients without 
epilepsy, depression, bipolar disorder or treatment with antiepileptic 
medication, 38.2 for every 100.000 persons/year among patients with 
epilepsy who were not treated with antiepileptic medication and 48.2 
for every 100.000 persons/year among patients with epilepsy taking 
antiepileptic medication. In the adjusted analysis, a risk associated to 
this medication taken as a whole was identified, both in patients who 
did not suffer from epilepsy (OR=1.6; CI 95%= 1.2-2.2) and in 
patients with depression or bipolar disorder (OR=2.6; CI 95%=1.8-
3.7), however, a greater risk of suicidal behaviour was not identified in 
patients with epilepsy (Arana A et al., 2010). The authors concluded 
that antiepileptic drugs were not associated with an increased risk of 
episodes related with suicide among patients with epilepsy but they 
were indeed in the case of patients with depression and those who did 
not suffer from epilepsy, depression or bipolar disorder. Other studies 
did not find an increased risk of suicide attempts or consummated 
suicides associated with the use of different antiepileptic drugs in 
patients diagnosed with bipolar disorder (Nilsson L et al., 2002; Leon 
AC et al., 2012). A recent prospective and observational study from 
2015 has assessed the action of lamotrigine in a sample of 969 
 patients with bipolar disorder (Rihmer Z et al., 2015). At the start of 
the study, 17% of patients showed a clinically significant suicide risk 
that went down gradually to 2.1%. During the six-month study period, 
there was no suicide attempt or consummated suicide.   
 
1.5.3. Antipsychotics 
 
Antipsychotics achieved the so-called deinstitutionalization, that is, 
psychiatric patients going out of the old asylums and mental 
institutions. However, even though patients under treatment with 
those drugs might live outside traditional enclosed institutions, there 
is, for the purpose that concerns us, a greater risk of suicide. It is 
estimated that up to 40% of patients with schizophrenia will try to 
commit suicide at least once in the course of their illness (Barak Y et 
al., 2004).  
 
There is evidence to suggest that atypical antipsychotics, apart from 
having therapeutic effects over depression and hostility, can also 
reduce suicidal behaviour in schizophrenics due to their action over the 
5-HT2A receptors since aggression and suicide ideas are directly 
related to the increase of the expression of these receptors in the 
prefrontal cortex (Mann JJ et al., 1986; Pandey GN et al., 1990; Keck 
PE Jr et al., 2000).  
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Soon after the first antipsychotics were introduced in medicine, an 
increase of the incidence of suicides in the population of hospitalized 
schizophrenics was   observed in some studies (Beisser AR et al., 
1961; Husar AF, 1962) but some older studies did not find these 
differences (Cohen S et al., 1964). Apparently a significant number of 
suicides took place after an abrupt interruption of the treatment with 
antipsychotics. Consistent with the observations above are the results 
of another study in which individuals from a sample of schizophrenic 
patients who were kept stable for 12 and 48 months through 
neuroleptic treatment were randomly distributed between two groups, 
one which maintained the neuroleptic treatment and another in which 
it was withdrawn (Johnson DA et al., 1983); the cases of suicidal 
behaviour increased significantly in the untreated group: for a tracking 
period of 18 months suicidal behaviours were observed in 27% of the 
untreated group as opposed to 11% of the group taking the 
neuroleptic medication. Likewise, a retrospective study of 88 
schizophrenic patients who took their lives found that a considerable 
proportion of patients were not taking the antipsychotic treatment at 
the correct dose, did not follow the treatment or did not respond to an 
adequate antipsychotic treatment (Heilä H et al., 1999). It was also 
found that the majority of suicides, 78% of the total sample took place 
during an active stage of the illness and from that number, only 54% 
 were being treated with the correct dose of antipsychotics, which led 
the authors to conclude that it is necessary to improve the treatment 
of these patients, especially in the active stage, with the goal of 
reducing the risk of suicide. In more recent studies, the effects of the 
different antipsychotics, in this respect, have been analyses; it was 
observed for instance that olanzapine, an antipsychotic with low risk of 
inducing extrapyramidal reactions, decreases suicidal behaviour to a 
greater extent than haloperidol (Beasley CM et al., 1998). Besides, it 
has been noticed that clozapine, risperidone, olanzapine, quetiapine 
and ziprasidone might be useful in the treatment of psychotic disorders 
with frequent symptoms of hostility, depression and suicidal tendencies 
(Keck PE Jr et al., 2000). In other studies, quetiapine and other 
atypical antipsychotics like aripiprazol (Ulcickas Yood M et al., 2010; 
Nishiyama A et al., 2013) were neither associated with a greater risk 
of suicide. Clozapine has the most protective action of all 
antipsychotics; in 2003 its use was approved for this indication by the 
FDA (Beasley CM et al., 1998). Clozapine action has been studied in 
patients with schizophrenia resistant to treatment who had had one or 
more suicide attempts comparing it with another group of patients who 
were not taking it (Duggan A et al., 2003). It was observed that the 
use of clozapine not only improved the typical symptoms of the illness 
but also prevented the appearance of suicidal behaviour. Consequently, 
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in view of the results of the different studies, it seems to exist a 
certain protective effect, at least in the case of atypical antipsychotics 
as regards suicidal behaviour. There are several mechanisms that 
would explain the decrease of suicidal behaviour in the case of atypical 
antipsychotics. In the first place, the profile of more favourable side 
effects of atypical antipsychotics promotes adherence to the treatment 
and improves therapeutic efficacy (Marazziti D et al,.2005). On the 
other hand, it is worth noting a greater reduction of the psychotic 
symptoms and the effects over impulsivity as well as the alleviation of 
the affective symptoms with the corresponding enhancement of social 
interaction (Barak Y et al., 2004). 
Recently, a population-based cohort study has been developed in Swe-
den with patients taking different types of antipsychotics as treatment for 
schizophrenia (n = 26,046) (Ringbäck Weitoft G et al., 2014). After being 
adjusted for age and gender, the patients treated with clozapine showed a 
smaller risk of death by suicide (OR=0.4; CI 95%=0.2-1.0) and suicide 
attempts (OR=0.4; CI 95%=0.3-0.7) than those treated with haloperidol; 
the study concluded that clozapine and olanzapine as well reduce the risk 
of suicide attempt, and the frequency of rehospitalization. 
 
1.5.4. Benzodiazepines 
 
Depression, as has been said before, favours the appearance of 
 suicidal behaviour, especially when patients face a period of intense 
anxiety (Lecrubier Y, 1998). As a result, the probability of suicide 
attempts would be greater when the depression is associated with an 
anxiety disorder or social phobia (Weissman MM et al., 1989). In a 
study on this particular conducted in France including more than 4,000 
patients it was concluded that: a) anxiety and depression coexist in 
41.9% of the cases; b) benzodiazepines have no effect over 
depression and many anxiety disorders, in spite of the prolonged 
treatments; c) in coping with affective disorders, the first line of 
treatment should be SSRIs, but not benzodiacepines (Pélissolo A et al., 
2007).  
 
However, given that antidepressants take a few weeks to take effect, 
the expected benefits of benodiacepines would be mainly to obtain an 
immediate improvement of the anxiety associated with depression 
(Doraiswamy PM, 2001). Therefore, the anxiety reduction would prove 
beneficial in dealing with patients with suicidal ideation and the use of 
anxiolytics like benzodiacepines would be advisable for many of those 
patients (Sachs GS et al., 2001). Paradoxically, numerous studies have 
identified an association between the use of benzodiacepines and the 
appearance of suicidal behaviour. A decline has been observed of 
peripheral receptors of benzodiazepines in hospitalized adolescents 
with a record of suicide attempts (Marazziti D et al., 2005) and in 
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schizophrenic patients who had attempted suicide in a violent way 
(Ritsner M et al., 2003). With diazepam, an increase of self-aggressive 
conduct has been described in an experiment (Berman ME et al., 
2005). In the said experiment, volunteers could choose a form of 
aggression (electric shocks) through a task based on time of reaction; 
it was found that those who had taken diazepam chose the maximum 
intensity in the applied shock, which was even more evident in 
individuals with a hostile personality (Ben-Porath DD et al., 2002) and 
the same results were repeated using alprazolam (Bond AJ et al., 
1995). Flunitrazepam and nitrazepam were also found in the plasma of 
corpses of elderly suicide victims (Carlsten A et al., 2003). Some 
connection between suicide and the use of alprazolam has also been 
described (Kravitz HM y et al., 1993). The appearance of behaviour 
disinhibition, death thoughts, suicide attempts and self-mutilation have 
been described with the use of clonazepam (Kandemir H et al., 2008). 
It has been noted that the changes in the regimen of benzodiacepines 
could lead to autolysis phenomena (Neale G et al., 2007).  
 
In conclusion, we know that depression is typically accompanied by 
anxiety and, in both cases, suicidal bevaviour may be present 
(Jiménez-López JL et al., 2015). Although benzodiacepines could be 
employed as adjuvant therapy to other drugs so as to improve anxiety, 
 it has to be noted that their benefits in the long run are questionable 
and should be watched closely (Gilbert DA et al., 1998; American 
Psychiatric Association, 2008). The use of benzodiacepines should be 
applied at moderately low doses and watch as well the possible 
behavioural disinhibition that might favour suicidal behaviour (Bousoño 
M et al., 1990). 
 
1.5.5. Analgesics 
 
Analgesics are used, among other situations, in cases involving 
chronic pain. Numerous studies reveal that patients with pain are more 
prone to depression than patients without it. Besides, the presence of 
pain can obscure the detection and treatment of depression, increasing 
the risk of suicide (Cheatle MD, 2011; Moix J et al., 2011).  
 
1.5.5.1. Opioid analgesics 
 
Several explanations have been provided for the relationship 
between pain and suicidal behaviour. There are areas of the brain 
involved both in the control of pain and in the adjustment of emotions 
(Ochsner KN et al., 2005; Ribeiro SC et al., 2005). In some of these 
areas –for example, the anterior cingulate cortex- there is a great 
number of opioid receptors (Zubieta JK et al., 2001). It has been 
observed that there is an alteration in the opioid receptors of the 
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brains of suicide victims (Sher L et al., 2008).  
 
Endogen opioids are involved in a wide range of processes in the 
nervous system, including modulation of reward, pain and emotions 
(Ribeiro SC et al., 2005; Roth-Deri I et al., 2008).  
This way, the modification of pain perception present in people 
suffering from depression and that may condition suicide vulnerability 
is connected with the opioid system (Olié E et al., 2013). Given the 
juxtaposition of the systems involved in the regulation of affection and 
pain, it seems reasonable to suppose that the alteration of a type of 
sensation such as pain might lead to an alteration of mood. (Bresin K 
et al., 2013).  
 
An increased analgesic consumption in patients with a history of 
suicidal behaviour suggests the existence of an increased sensitivity to 
pain in those patients (Olié E et al., 2013). On another note, some 
studies have proved that psychiatric illness is a risk factor for analgesic 
intoxication (Skegg K, 2005) and, at the same time, such intoxication 
could be a risk marker for the appearance of later psychiatric disorders 
(Jepsen P et al., 2005).  
 
Persons with a record of suicide attempts are more prone to the 
consumption of analgesics than those without it (Olié E et al., 2013). 
The consumption of opioids is signficantly increased in individuals with 
 a history of depression and previous suicide attempts. It also appears 
that a history of intoxication by analgesics is a predictor of a later 
consummated suicide (Welcher B et al., 1993; Hawton K et al., 2003). 
Intensive and frequent monitoring of patients taking this medication 
for the first time and avoiding the prescription of long-acting opioids 
might help to prevent suicide attempts (Im JJ et al., 2015).  
 
1.5.5.2.   Non-opioid analgesics 
 
It is understood that the neurological substrate of physical pain is 
activated as well by psychic discomfort (“mental pain”). This 
discomfort is associated as well with suicide risk and, consequently, 
this risk could dwindle with analgesic intake including opioids and 
ketamine (Gaillard R et al., 2010). A study has been carried out to 
assess the effect of paracetamol consumption over certain emotions 
(Durso GR et al., 2015). The participants taking this drug tolerated 
better being exposed to unpleasant emotional stimuli in comparison 
with the participants taking a placebo. The stimuli that they were 
exposed to (both negative and positive) entailed a smaller emotional 
load in comparison with the individuals taking a placebo.   
 
However, the relationship presented between the existence of 
chronic pain and the appearance of death thoughts and suicidal 
behaviour is frequent. It is estimated that up to 50% of patients with 
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chronic pain have suicidal ideation (Hitchcock LS et al., 1994). Thus, 
some countries have considered the availability and use of analgesics 
as part of the strategies of suicide prevention (Simkin S et al., 2012; 
Madadi P et al., 2014). That said, the exact origin of an overdose is 
unclear since it might include an accidental overdose in the case of 
patients trying to alleviate the suffering of poorly controlled pain or 
induce sleep (Scott KM et al. 2010). Nevertheless, distinguishing what 
proportion of these cases is connected with intentional death by 
suicide and how many deaths are caused by accidental overdoses is 
complicated due to the existence of classification errors. Therefore, the 
relationship between analgesic consumption and suicide should be 
further investigated.  
 
1.5.6. Justification or expected usefulness of the study 
 
The importance of this study lies in the possibility of preventing the 
onset of suicidal behaviour. A better understanding of suicidal 
behaviour allows the introduction of prevention schemes and the 
prevention of suicidal behaviour would diminish the costs of 
therapeutic interventions.  
 
Another aspect to take into consideration is the improvement of the 
quality of life of the population and especially those patients with a 
greater suicide risk who might benefit from these prevention schemes.  
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2. Goals 
 
 
2.1. General goals 
 
- The goal of this essay is to find out whether there is a connection 
between the consumption of certain drugs and the appearance of 
suicidal behaviour.  
 
 
2.2. Specific goals: 
 
- Analyse the risk of attempting suicide of patients taking 
antidepressants.   
- Analyse the suicide risk of patients taking anxiolytics 
(benzodiacepines). 
- Analyse the suicide risk of patients taking antipsychotics.  
- Analyse the suicide risk of patients taking antiepileptics. 
- Analyse the suicide risk of patients taking analgesics (opioids and 
non-opioids). 
- Know the variables that have an influence over the suicide risk 
associated with drugs.  
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3. Material and method  
 
3.1. Study design 
 
In order to learn about the association between suicide behaviour 
and the different risk factors considered, a study of retrospective cases 
and controls was conducted. Two groups of individuals were compared 
according to whether they had had a suicide attempt (cases) or not 
(controls). The groups formed in such a way were compared in 
accordanc with the exposure to the different drugs studied and other 
variables of interest. The aim was to obtain an estimator of the 
strength of the association between one or several risk factors and the 
outcome of interest.  
 
This estimator is called odds ratio (OR) and is represented by the 
Greek letter psi (Ψ). When a small proportion of the population is 
affected by an illness, as is the case with rare diseases, the number of 
exposed cases (a) is very small compared to the number of exposed 
controls (b) and the number of unexposed cases (c) is very small 
compared to the number of unexposed controls (d). In this situation, 
the value of OR approximates (a x d) / (b x c). The OR indicates how 
many more times the cases are exposed with respect to the controls. 
Table 1 shows the organization of results in a 2x2 table and the 
corresponding estimation of risk.  
 Table 1. Positioning of data for the calculation of OR (2x2 table) 
 
 Presence 
illness 
Absence 
illness 
 
Total 
Exposed a b a+b 
Unexposed c d c+d 
Total a+c b+d a+b+c+d 
 
OR=axd/cxb 
 
An odds ratio of 1, or not significantly different from 1, would 
indicate that there is no association between the considered risk factor 
and the illness studied.  Conversely, an odds ratio value higher than 1 
would indicate that this factor is associated with the illness as causal 
factor. The contrary would happen if the odds ratio value is lower than 
1, in this case we would consider it a protective factor. The odds ratio 
value must be accompanied by a confidence interval, in general 95%. 
This confidence interval is an indicator of the precision of the 
estimation and the statistical significance of the association, and 
provides more information than the test value of χ2 and its associated 
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probability (p). The smaller the confidence interval, the more reliable 
the results of the association analysis. One of the disadvantages of this 
type of study is the possibility of introducing a bias which is difficult to 
detect.  
 
3.2. Study development  
 
The period of identification of patients of interest and data collection 
went from January 2000 to January 2004. For each case, two controls 
were identified which were matched to the cases by age (with a 
difference of more/less 5 years), gender and period of hospitalization 
(more/less three months from the date of admission).  
 
3.3. Selection of cases 
 
For the purposes of this study they were considered as cases those 
patients over 18 years old who were hospitalized in the Short-Term 
Psychiatric Unit after having attempted suicide during the period of 
study. However, different exclusion criteria were also considered as 
follows: 
 
Exclusion criteria: patients under 18 years old were excluded and so 
were patients whose medical history did not include accurately the 
medication they were taking in the months previous to the hospital 
admission. Those cases in which the patient did not take the 
 personality test with the application of the MCMI-III questionnaire 
during admission (see appendices) were also excluded. 
 
It was considered that patients were exposed to each of the drugs 
studied when there was a prescription of the said drugs in their 
medical history in the three months previous to the index day, day in 
which the suicide attempt which motivated hospital admission took 
place.  
 
3.4. Selection of controls 
 
Patients who were considered adequate controls for the identified 
and selected cases were patients over 18 years old hospitalized in the 
Short-Term Psychiatric Unit in the same period (more/less 3 months 
from the date of admission) whose reason for admission might be any, 
other than having attempted suicide. The criteria for exclusion were 
the same as in the cases. 
 
3.5. Data collection for the study 
 
The information about patients was obtained from the computer-
based clinical records and in physical format from the general register 
of clinical records of the University Health Complex of Palencia 
(Complejo Asistencial Universitario de Palencia). The digital records 
with clinical information are available from the year 2005 to this day. 
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The study also included the paper documentation including the 
previous period from the year 2000 to 2004.  Collection of information 
took place in the hospital environment (San Telmo and Rio Carrión 
hospitals, both in Palencia). Valid information was collected for a total 
sample of 1,680 patients from which 560 were controls and 1,120 the 
total of the cases.  
 
 
3.6. Included variables 
 
The variables analysed in the study are specified below:  
a) Sociodemographic variables:  
 
- Age (continuous variable in years) 
- Gender (male/female) 
- Marital status (single/married/separated-divorced/widowed) 
 
b) Variables related with suicidal behaviour or with clinical severity:  
- Psychiatric background (according to DSM-IV criteria) 
- Number of previous suicide attempts  
- Family history (first degree) of suicide (yes/no) 
- Number of visits to Emergency for all reasons 
 
    c) Variables related with the consumption of addictive substances 
(dichotomous variabes yes/no)  
 
- Tobacco consumption 
- Alcohol consumption 
- Cannabis consumption 
- Cocaine consumption 
- Heroine consumption 
- Amphetamine consumption 
 
   d) Variables related with the pathology  
 
- Main somatic diagnosis (according to CIE-10 criteria) 
- Main psychiatric diagnosis (according to DSM-IV criteria) 
- Diagnosis of major depression in the first three months pre-
vious to the index day (according to DSM-IV criteria) 
(yes/no) 
- Personality (according to MCMI-III items)  
 
e) Variables related to the consumption of drugs in the first three 
months previous to hospital admission (dichotomous variables 
yes/no): 
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  - Consumption of antipsychotics 
         - Consumption of antidepressants 
         - Consumption of SSRIs 
         - Consumption of antiepileptics 
         - Consumption of anxiolytics (benzodiacepines) 
         - Consumption of opioid analgesics 
        -  Consumption of non-opioid analgesics 
 
As regards the variables related with the pathology, the main 
somatic and psychiatric diagnoses were collected. The non-psychiatric 
diagnosis was the one present in the clinical history of the patient. This 
diagnosis had to be made in the three months prior to admission, both 
in the cases and controls. The main psychiatric diagnosis was the one 
present in the hospital discharge report after admission, both in the 
cases and controls.  
 
Apart from the main psychiatric diagnosis, the major depression 
diagnosis was collected due to its special interest as an independent 
variable. This diagnosis had to have been made in the three months 
prior to hospital admission (index day), both in the cases and controls.  
 
For this purpose, the clinical history of the sample patients was 
revised retrospectively. Information about the personality of the cases 
was also collected, taking into consideration the score on MCMI-III 
 items. In every case, the feature with the highest score was chosen 
and the rest were excluded.  
 
All the information contained in this interview was collected in an 
Excel data base designed for that purpose and adjusted later. In order 
to maintain patient anonymity, a unique numerical code was assigned 
to the new records generated, so that during data processing, it was 
impossible to associate them with any specific patient. 
 
3.7. Statistical analysis 
 
In the descriptive analysis of the sample, there are absolute 
frequencies (n) and relative (percentage) for the categorical variables 
and the mean with its standard deviation (SD) for the numerical 
variables. The differences between groups were analysed through 
Pearson´s Chi Square test. For the first variables and through 
Student´s T-Test for the second. Logistic regression was used to 
analyse the possible relationship between the consumption of some 
drugs and suicide attempts. The results feature the Odds Ratio (OR), 
raw and adjusted, with their confidence interval of 95% (CI 95%). 
Adjusted OR corresponds with a final model, obtained through the 
procedure of successive steps forward. This procedure was the one 
chosen, once possible interaction and confusion effects were analysed 
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and discarded between the different factors and covariables 
considered. Thus, successive models of regression executed with 
different procedures were posed. The suitability of the adjustment was 
assessed with the Hosmer-Lemeshow test.  
 
To make sure that the possible colinearity between the variables did 
not produce a degradation in the estimations of the parameters, the 
variance inflation factors were taken into account (VIF). As a general 
rule VIFs lower than 10 are acceptable (Belsley DA et al., 1980).  
 
As a measure of the capacity to discriminate (degree to which the 
model distinguishes individuals attempting suicide and those who do 
not), the area under the ROC curve (Received Operative Curve) is 
presented, built with the probability of the attempt predicted by the 
model for each of the records of the study (cases and controls).  
 
The statistical analysis was carried out with the programme SPSS 
v.20.0. The level of statistical significance was established at p≤0.05 
for all tests. 
    
 
 
  
3.8. Ethical and legal aspects 
 
This study has taken every precaution to ensure the confidentiality 
of the personal data of the patients included in the sample. It has been 
approved by the Clinical Investigation Committee of the University of 
Palencia (Complejo Asistencial Universitario de Palencia)*.   
*Appendices. 
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4. Results  
The final sample – with valid information- consisted of 1,680 
patients, 560 cases and 1,120 controls. Table 2 displays the 
distribution, between the cases and controls, of the main dependent 
variables considered in the study.  
 
Table 2. Sample variables. Distribution between the cases and 
controls. 
 n (%)  
 Controls (n=1,120) Cases (n=560)  
Age (years; SD) 38.5; 15.3 38.0; 15.3 P = 0.474 
Gender     
male 406 (36.3) 181 (32.3) P = 0.111 
female 714 (63.8) 379 (67.7)  
Marital status    
single 373 (33.3) 277 (49.5) P < 0.0001 
Married  551 (49.2) 197 (35.2)  
divorced 117 (10.4) 62 (11.1)  
widowed 79 (7.1)   24 (4.3)  
Suicide attempt    
yes 95 (8.5) 134 (23.9) P < 0.0001 
no 1025 (91.5) 426 (76.1)  
Main  diagnosis, depression    
yes 200 (17.9) 276 (49.3) P < 0.0001 
no 920 (82.1) 284 (50.7)  
Consumption of abuse substances    
yes 831 (74.2) 331 (59.1)  
no 289 (25.8) 229 (40.9) P < 0.0001 
 
 Table 3 shows the consumption of different drugs (antidepressants, 
antiepileptics, antipsychotics and analgesics) that the patients were 
taking in the three months prior to admission for a suicide attempt. 
 
 
Tabla 3. Exposure to drugs. Distribution of exposure between cases 
and controls. 
      n (%) 
  
Controls (n=1,120) 
   
Cases (n=560) 
 
Antidepressants    
yes 730 (65.2) 413 (73.8) p < 0.0001 
no 390 (34.8) 147(26.3)  
Antipsychotics   
yes 698 (62.3) 146 (26.1) p < 0.0001 
no 422 (37.7) 414 (73.9)  
Anticonvulsants   
yes 342 (30.5) 115 (20.5) p < 0.0001 
no 778 (69.5) 445 (79.5)  
Benzodiacepines    
yes 797 (71.2) 399 (71.3) p=0.970 
no 323 (28.8) 161 (28.8)  
Non-opioid analgesics     
yes 268 (23.9) 336 (60) p < 0.0001 
no 852 (76.1) 224 (40)  
Opioid analgesics     
yes 47 (4.2) 28 (5.0) p=0.452 
no 1037 (95.8) 532 (95.0)  
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The consumption of alcohol, tobacco and illegal toxic substances 
(cannabis, cocaine, heroine and amphetamines) of the patients is 
presented in table 4.  
 
Table 4. Exposure to toxic substances. Distribution of exposure 
between cases and controls. 
 
n (%) 
 Controls (n=1,120) Cases (n=560)  
Tobacco    
yes 663 (59.2) 249 (44.5) p<0.0001 
no 457 (40.8) 311(55.5)  
Alcohol    
yes 340 (30.4) 203 (36.3) P=0.015 
no 780 (69.6) 357 (63.8)  
Cannabis    
yes 135 (12.1) 72 (12.9) p=0.637 
no 985 (87.9) 488 (87.1)  
Cocaine    
yes 18 (1.6) 27 (4.8) P<0.0001 
no 1102 (98.4) 533 (95.2)  
Heroine    
yes 6 (0.5) 2 (0.4) P=0.616 
no 1114 (99.5) 558 (99.6)  
Amphetamines    
yes 6 (0.5) 9 (1.6) P=0.028 
no 1114 (99.5) 551 (98.4)  
 
 Tables 5 and 6 include the distribution between the cases and 
controls of the different psychiatric and somatic pathologies 
respectively. 
 
Tabla 5. Psychiatric pathologies. Distribution between cases and 
controls.  
 n (%)  
 Controls (n=1,120) Cases (n=560) 
Affective disorders 334 (29.9) 340 (60.7) 
Major depression 200 (17.9) 276 (49.3) 
Bipolar disorder 94 (8.4) 11 (2.0) 
Dysthymia 40 (3.6) 53 (9.5) 
Anxiety disorders 80 (7.1) 29 (5.2) 
Unspecified anxiety disorder 27 (2.4) 20 (3.6) 
Generalized anxiety disorder 36 (3.2) 0 
Obsessive-compulsive disorder 17 (1.5) 9 (1.6) 
Eating habits disorders 64 (5.7) 0 
Sleep disorders 20 (1.8) 0 
Adjustment disorders 153 (13.7) 34 (6.1) 
Personality disorders 150 (13.4) 55 (9.8) 
Substance abuse disorders 42 (3.8) 16 (2.9) 
Cognitive deterioration 0 (0) 8 (1.4) 
Psychotic disorders 214 (19.1) 62 (11.1) 
Schizophrenia 135 (7) 60 (0.4) 
Delusional disorder 39 (3.5) 2 (0.4) 
Schizoaffective disorder 24 (2.1) 0 
Toxic psychosis 16(1.4) 0 
Impulse control disorders 2 (0.2) 0 
Undiagnosed 61 (5.4) 16 (2.9) 
Results 
 
99 
The most prevalent non-psychiatric pathologies among the cases 
were, in decreasing order, musculoskeletal, neurological and 
oncological (Table 6). A variable percentage, greater among the 
controls, did not have a consigned somatic diagnosis. 
 
Table 6.  Somatic pathologies. Distribution among cases and controls 
 
 
n (%) 
Controls (n=1,120) Cases (n=560) 
Cardiovascular 86 (7.7) 5 (0.9) 
Pulmonary 7 (0.6) 0 
Neurological 45 (4.0) 134 (23.9) 
Genitourinary 8 (0.7) 2 (0.4) 
Gastrointestinal 87 (7.8) 48 (8.6) 
Endocrine-metabolic 37 (3.3) 5 (0.9) 
Musculoskeletal 199 (17.8) 249 (44.5) 
Ocular 8 (0.7) 0 
Dermatological 9 (0.8) 0 
Infectious 6 (0.5) 2 (0.4) 
Oncological 58 (5.2) 48 (8.6) 
Hematological 12 (1.1) 1 (0.2) 
Respiratory 62 (5.5) 0 (0) 
Nephrological 14 (1.3) 1 (0.2) 
Immunological 10 (0.9) 0 
Undiagnosed 472 (42.1) 65 (11.6) 
 
 
 
 Figure 5 shows the personality traits which are most frequent among 
the cases and their distribution by gender. There were no significant 
differences in the personality types between men and women 
(X29=9.836; p=0.364). 
 
Figure 5.  Personality of the cases (percentage for men and women). 
 
 
As we can observe, 63.8% of the cases scored higher in the items 
corresponding to borderline personality. The patients with dependent 
personality were in second place and with a much smaller prevalence, 
making up 15% of the cases. Next were the schizoid and schizotypal 
features, with similar frequencies (5.7% and 4.5%, respectively). As 
for the rest of personality types, 3% of the cases had histrionic 
personality traits, 2.5% paranoid and 2% antisocial. The least 
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prevalent personality trais among the cases were the ones 
corresponding with the following personalities: avoidant (1.6%), 
narcissist (1.1%) and obsessive (0.9%) (see appendices). On the 
other hand, figure 6 shows in percentage the types of suicide attempt 
carried out by men and women. There are significant differences as 
regards the different methods employed by men and women 
(X26=7.72; p<0.0001). 
 
Figure 6. Suicide methods among the cases (percentages in men, 
women and total). 
 
The most frequently employed method for the suicide attempts was 
intoxication with medication (56%); women resorted to this procedure 
 with more frequency. The second most common method, with a 
percentage of 30.1%, was self-injury, with no differences between 
men and women given the similar values (30.9% and 29.6%, 
respectively). With much less frequency the cases in the sample made 
use of other self-injury methods like defenestration (5.0%), hanging 
(3.2%), gas intoxication (3.0%) and drowning (0.7%). In all these 
methods the difference between men and women turned out to be 
significant. Men used more often methods of greater lethality, like 
defenestration (6.6% in men and 4.2% in women) and hanging (7.2% 
in the case of men and 1.3% in the case of women). As regards 
drowning, the percentage was greater in the case of men (1.1%) than 
women (0.5%) (see appendices).  
 
Figure 7 shows previous suicide attempts; 58.4% of the cases had 
had autolythic attempts before (20.4% of men and 76.5% of women), 
with significant differences between the sexes (X2= 158.5; p< 
0.0001). 
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Figure 7. Previous suicide attempts by number of attempts (n=1,680) 
 
 
In accordance with the model of this study, different factors have 
been identified associated with a bigger or smaller probability of 
attempting suicide.  
 
As for the sociodemographic factors (Table 7), the risk of suicide 
attempt was greater for women than for men (adjusted OR [CI 95%]= 
1.88 (1.41-2.52), and the same happened with single patients with 
respect to the rest of the sample (OR=2.04; CI 95% =1.56-2.69).  
 
 
      On the other hand, the likelihood of a suicide attempt among 
patients with a family history of suicidal behaviour would be much 
higher than those patients without such a history (OR= 4.10; CI 
95%=2.79-6.03). Taking into account the main psychiatric diagnosis, 
the patients with a major depression diagnosis would be the ones with 
the highest risk (OR=3.77; CI 95%=2.82-5.06).  
 
Besides, regardless of whether the main psychiatric diagnosis 
was depression or any other psychiatric illness, the probability of a 
suicide attemp would be higher among those who had had symptoms 
of major depression diagnosed in the three months previous to 
hospital admission (OR=1.92; CI 95%=1.45-2.53).  
 
The presence of non-psychiatric comorbidity would also increase 
notably the risk of suicide in those patients (OR= 5.06; CI 95%=3.58-
7.15).  
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Table 7.  Suicide attempts and related factors. Estimation of the 
strength of the association. 
 
 
 
n (%) Raw OR (CI 
95%) 
Adjusted OR (CI 
95%) 
Controls Cases 
Gender, women 714 
(63.8%) 
379 
(67.7%) 
1.19 (0.96-
1.48) 
1.88 (1.41-2.52) 
Single 373 (33.3%) 
277 
(49.5%) 
1.96 (1.59-
2.41) 2.04 (1.56-2.69) 
Previous history a 95  (8.5%) 
134 
(23.9%) 
3.39 (2.55-
4.52) 4.10 (2.79-6.03) 
Depression b 331 (29.6%) 
263 
(47.0%) 
2.11 (1.71-
2.60) 1.92 (1.45-2.53) 
Depression, main 
diagnosis 
200 
(17.9%) 
276 
(49.3%) 
4,47 (3.57-
5.60) 3.77 (2.82-5.06) 
Another pathologyc 647 (57.8%) 
495 
(88.4%) 
5.57 (4.19-
7.40) 5.06 (3.58-7.15) 
 
a  Previous family history of suicide 
b Major depression diagnosed in the three months prior to the suicide 
attempt  
c Another non-psychiatric pathology, one or several diagnoses 
 
 
Table 8 describes the association between the consumption of the 
medication of interest and the risk of appearance of suicide attempts. 
 
  
Table 8. Suicide attempts and medication. Estimation of the strength 
of the association 
 
 n (%) 
Raw OR (CI 95%) Adjusted OR (CI 95%) 
Medication  Controls  Cases 
SSRIs 416 
(37.1%) 
301 
(53.8%) 
1.97 (1.60-2.42) 1.67 (1.27-2.19) 
Antipsychotics 698 
(62.3%) 
146 
(26.1%) 
0.21 (0.17-0.27) 0.19 (0.15-0.26) 
Opioid analgesics 47  
(4.2%) 
28 
(5.0%) 
0.83 (0.52-1.34) 0.42 (0.23-0.76) 
Other 
analgesics  
268 
(23.9%) 
336 
(60.0%) 
4.77 (3.84-5.93) 3.96 (3.01-5.22) 
 
   
  There would be a greater risk of suicide among patients under 
treatment with SSRIs (OR=1.7; CI 95%=1.27-2.19), and even greater 
in those patients under treatment with non-opioid analgesics 
(OR=3.96; CI 95%=3.01-5.22). Nevertheless, the treatment with 
antipsychotics would diminish the probability of committing a suicide 
attempt (OR=0.2; CI 95%=0.15-0.26) and the same would apply in 
the case of opioid analgesic consumption (OR=0.4; CI 95%=0.23-
0.76). Other independent factors associated with the risk of suicide 
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attempts are related with the intake of several substances such as 
alcohol, tobacco and certain illegal drugs (Table 9). 
 
Table 9. Suicide attempts and consumption of toxic substances. 
Estimation of the strength of the association. 
 
 n(%) 
Raw OR (CI 
95%) 
Adjusted OR (CI 
95%) Toxic 
substances 
Controls Cases 
Tobacco 663 
(52.9%) 
249 
(44.5%) 
0.55 (0.45-0.68) 0.58 (0.44-0.78) 
Cannabis 135 
(12.1%) 
72  
(12.9%) 
1.08 (0.79-1.46) 2.07 (1.35-3.19) 
Cocaine 12  
(1.6%) 
27  
(4.8%) 
3.10 (1.69-5.68) 3.67 (1.60-8.39) 
 
 
Consumption of cannabis would increase the risk of a suicide 
attempt (OR=2.1; CI 95%= 1.35-3.19); the risk of such an attempt 
would be even greater among consumers of cocaine (OR=3.7; CI 
95%= 1.60-8.39). However, in connection with the consumption of 
toxic substances, being a smoker would be associated with a decrease 
of the risk of a suicide attempt (OR= 0.6; CI 95%=0.4-0.8).  
 
In total, 13 independent risk factors were identified related to the 
suicide attempt. The model of logistic regression shows good 
 calibration (Hosmer-Lemeshow test=7.038; p=0.532) and good 
capacity to discriminate between cases and controls (Area below the 
curve and confidence interval at 95%= ABC [CI 95%]= 0.880 [0.863-
0.897]; p< 0.0001). Figure 8 shows the ROC (Receiver Operating 
Characteristic) curve built with the probability of suicide attempt 
predicted by the model.  
   
Figure 8. ROC curve (Receiver Operating Characteristic) for the 
probability of suicide attempt predicted by the model of logistic 
regression. 
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5. Discussion 
 
Suicide makes up one the first causes of death in developed 
countries and constitutes a severe problem of public health. It has 
been estimated that in the year 2013 842,000 deaths by suicide took 
place all over the world (World Health Organization, 2012; Pitman A et 
al., 2012). The problem, far from decreasing, is growing and it has 
been estimated that the death toll for this cause rose by 60% between 
the year 1960 and 2012 (World Health Organization, 2012). 
Nevertheless, it is a complex issue and it can stated that, apart from 
clear risk factors like psychiatric illness, there are other contributing 
factors whose identification will allow us to better understand the 
multicausal dimension of the phenomenon and tackle its prevention. 
The importance of biological factors, so relevant these days, might be 
pointed out.  
 
Enzyme protein kinase A, an essential component of the signal 
transduction pathway of adenyl cyclase, has been identified as a 
possible predictive factor (Dwivedi Y et al., 2011). This enzyme is 
involved in genetic transcription and cellular plasticity and survival. As 
far as we are concerned, drugs have been associated with suicide or 
more specifically with suicidal behaviour. Recent studies have tested 
the relationship between some drugs, of common use in different 
 areas other than psychiatry, and suicidal behaviour, among these are 
corticosteroids (Fardet L et al., 2012), isotretionine (Sundström A et 
al., 2010), varenicline and bupropion used in the supression of the 
smoking habit (Thomas KH et al., 2013; Gibbons RD et al., 2013), 
antiasthmatic leukotriene modulators (Schumock GT et al., 2012) and 
efavirenz (Mollan KR et al., 2014). 
 
Our study of an observational nature has analysed the existing 
relatonship between psychotropic substances and analgesics and 
suicidal behaviour. One of the most worrying problems of this type of 
studies is the comparability of the groups. In our case-control study, 
the comparability of the case group with the control group. In order to 
make the groups comparable, we have resorted to matching by 
important predictive variables and the adjustment of the statistical 
analysis.   
 
The matching employed achieved a balance in the distribution of 
patients by sex and age in the two groups being compared (Table 2); 
other variables, as expected, had an unequal distribution. As regards 
marital status, for instance, single and divorced patients represented a 
bigger percentage in the cases than in the controls. If we adscribe 
some civil statuses like being single, divorced or widowed with the 
situation of living alone, of isolation, that situation in general would be 
Discussion 
 
115 
more frequent in the cases. Other risk factors like the major 
depression diagnosis or the previous suicide attempt were more 
frequent in the cases. The major depression diagnosis as main 
diagnosis at the time of admission and a previous history of suicide 
attempts were in effect distributed unevenly: among the cases, 49.3% 
had a major depression diagnosis as opposed to 17.9% among the 
controls. For the suicide attempts, these percentages were 23.9% and 
8.5%, respectively. 
 
The diagnosis of affective disorder which includes depression and 
mania and all the intermediate stages was more frequent among the 
cases than among the controls, but this was not the case for the 
diagnoses of anxiety, adjustment, personality or psychotic disorders. 
The connection of all these disorders with suicidal behaviour has been 
thoroughly studied (Isometsä ET, 2001; Muehlenkamp JJ et al., 2011; 
Glenn CR et al., 2013). 
It is well known that one of the distinctive features of depression in 
particular is suicidal ideation and it is this symptom precisely what 
makes this disorder so serious. However, an excessive medicalisation 
of the psychiatric illness makes it difficult to understand the true 
relationship between the illness and the suicidal thoughts. It is also 
difficult to establish the connection between the somatic illness and 
 the suicidal behaviour. One striking aspect is the fact that the 
frequency of these diagnoses of somatic illnesses is greater in the 
cases: for the cases, the percentage of patients diagnosed was almost 
90%, whereas for the controls this percentage did not reach 60%. It is 
worth noting the high value of risk, the most elevated of all found in 
the study, for the patients with these non-psychiatric pathologies 
(OR=5.1; CI 95%=3.6-7.1). If we consider the diagnosis and its 
number as indicators of seriousness, the situation that these somatic 
diagnoses represent in the study is that the cases, regardless of the 
suicide thoughts, were more serious for reasons other than the 
controls.  This is corroborated if we take into account the percentage 
of specific diagnoses that would be a priori associated with a greater 
seriousness. Thus, neurological illnesses for instance had a relative 
frequency of 23.9% in the cases and 4% in the controls, 
musculoskeletal 44.5% and 17.8%, respectively and, similarly, 
oncological ones, with 8.6% and 5.2%. The notable exception was 
cardiovascular illnesses where these percentages were inverted, with 
0.9% in the cases and 7.7% in the controls. It is possible that the 
degree and intensity of pain in the different illnesses mentioned, apart 
from other circumstances like degree of disability that they cause 
could explain this different distribution. This coincides with the 
increase of suicide risk and consummated risk observed in a cohort of 
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220,336 patients after suffering a cerebrovascular accident (Eriksson 
M et al., 2015). This might also be consistent with the findings in a 
cohort of over 2,198 adults who suffered serious trauma (March J et 
al., 2014); when this group was compared with a control group 
(n=10,990), it was observed that the risk of suicidal behaviour was 
very high, even after adjustment for different variables (OR=3.3). 
  
Two sociodemographic factors were associated with a greater risk of 
suicide, namely being a woman and being single. It is a well-kown fact 
that women consummate suicide less than men, although the risk of a 
suicide attempt is greater among women (Miret M et al., 2010); as a 
result, with the same number of attempts women would have more 
failed attempts. It could be added that the more longevity of women 
would also partly explain the greater number of suicide attempts. Age, 
though, was a matching and adjustment factor. The fact that men 
resort to more lethal methods is difficult to explain without using 
commonplace clichés: a greater aggressiveness due to the 
predominance of male hormones. As for marital status, 49.5% of the 
cases were single as opposed to 33.3% of the controls, although being 
single does not necessarily imply living alone, if by that word we mean 
a certain isolation. On the one hand, this isolation could be understood 
as a risk factor for depression and suicidal behaviour. On the other 
 hand, it could be considered a risk marker: a person lives alone 
because they are ill and illness, in this case of a psychiatric nature, 
separates them from the others. Being single was associated with 
twice as much risk of suicide attempts in comparison with other 
marital statuses taken as a whole (OR=2.0; I CI 95%=1.6-2.7). The 
percentage of divorcees and widowed persons was 15.4% in the cases 
and 17.5% in the controls. It could be pointed out that marital status 
has little informative value; the situations in which people live today 
are very diverse and changing. As a predictive factor, and from a 
clinical point of view, it would be more useful to explore the real 
situation of cohabitation than the official marital status.  
 
A family history of suicide was associated with one of the hightest 
risks found (OR=4.1; CI 95%=2.8-6.0), very similar to the risk value 
that depression as main diagnosis entails (OR=3.8; CI 95%=2.8-5.1). 
The hereditary character of certain psychiatric illnesses associated with 
suicide and emotional contagion might explain this high risk value. 
 
The study has identified a significant risk of suicide attempt 
associated with SSRI antidepressants. This risk, in a wide sense of 
suicidal behaviour, has been identified in other studies and has given 
rise to different regulatory interventions. Even though there are well-
founded doubts about this risk and its magnitude since depression, 
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which tends to be the main cause for the use of these drugs, would be 
a confusion factor in the usual estimations. The cases of our study 
were exposed more frequently to antidepressants of any type than the 
controls (73.8% against 65.2%); this difference was even more 
marked for SSRI antidepressants (53.8% against 37.1%). In our 
study, the model used tries to adjust the risk estimation for different 
factors, among others the depression diagnosis. It is evident that the 
adjustment in our study gives rise to a modification of the raw risk of 
SSRIs (OR=2.0; CI 95%=1.6-2.4), which decreases (OR=1.7; CI 
95%=1.3-2.2), but continues in values close to 2 and, in any case, 
significant. In favour of our estimation it must be said that currently 
these drugs are used not only in the treatment of depression but also 
for other illnesses or conditions (both psychiatric - anxiety disorders or 
eating disorders - and somatic - migraine or irritable bowel - ) and as 
a result a great number of patients were taking this medication for 
conditions other than depression. It is difficult to know if these other 
conditions are also associated with suicidal ideation and behaviour. Our 
estimation partly coincides with the one observed in a recent study 
comprising 826 patients with bipolar disorder monitored for three and 
a half years (Toffol E et al., 2015). The said study identified a relative 
risk of suicide, mortality by suicide and mortality by other causes of 
1.5 (CI 95%=1.2-1.8). It is noteworthy that the type of patients and 
 their clinical circumstances, together with the type of dependent 
variable studied, could greatly influence the estimations. Our 
dependent variable, suicide attempt, althouth part of it, does not 
coincide with the compound variable used in the cited study.  
 
Antiepileptics were not associated with suicide attempts in our study. 
A percentage, smaller in the cases (20.5%) than in the controls 
(30.5%), was exposed to this medication. The drugs which make up 
this group are of a different chemical nature although they share a 
depressor effect over the CNS. However, their more specific 
mechanisms are quite different. Some of the oldest ones like valproic 
acid have been associated with an increase of overall risk of suicide 
attempts, death by suicide and by other causes (RR=1.5; CI 
95%=1.3-1.8); this has been observed in the study mentioned before 
including patients with bipolar disorder (Toffol E et al., 2015). The 
association of antiepileptics as a group with suicidal behaviour dates 
from 2008 when the FDA, based on the results of a meta-analysis, 
issued a warning on this particular (U.S. Food and Drug 
Administration, 2008); it was found that patients taking this 
medication had double the risk in comparison with the placebo. The 
study of Arana et al. (2010) also identified a risk associated with this 
medication taken as a whole, both in patients not suffering from 
epilepsy (OR=1.6; CI 95%= 1.2-2.2) and patients with depression or 
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bipolar disorder (OR=2.6; CI 95%=1.8-3.7); surprisingly, this study 
did not identify risk of suicidal behaviour in patients with epilepsy 
(Arana A et al., 2010). In our study, a high percentage of patients, as 
already stated, were diagnosed with affective disorders. Years after the 
warning issued by the FDA, the relationship between antiepileptics and 
suicidal behaviour remains controversial (Mula M et al., 2015). It is 
probable that the use in our sample of newer antiepileptics, perhaps 
deprived of this risk, might explain the abscence of risk found. In the 
context of psychiatric care, these antiepileptics are being used 
profusely as supposed 'mood stabilizers', as in the case of lamotrigine; 
this drug in particular has been associated with a decrease of suicide 
risk in a study including 969 patients being tracked for 6 months 
(Rihmer Z et al., 2015). The results that we have obtained in our study 
in connection with antiepileptics, namely the abscence of risk of 
suicide attempt, coincides with the observations of Pugh et al. (2013) 
in a cohort of more than 90,000 individuals (Pugh MJ et al., 2013). In 
this quasi-experimental 'before and after' study the probability of 
episodes of suicidal behaviour the month prior to the intake of 
antiepileptics was greater than the probability observed the month 
after the intake, nevertheless it must be pointed out that there were 
87 episodes the year before index day (74 individuals) and 106 the 
year after (92 individuals). Similarly, our results coincide with those of 
 Leon et al. (2012). In a retrospective study including 199 patients with 
bipolar disorder who provided 1,077 intervals of exposure or non-
exposure to antiepl¡leptics (carbamazepine, lamotrigine or valproato) 
an adjusted risk of 0.9 was estimated (CI 95%=0.4-1.9) (Leon AC et 
al., 2012). 
 
Antipsychotics are, just like antiepileptics, depressors of the CNS. It 
is no coincidence that they have been called 'chemical straitjackets'. 
The action mechanism that has been related to their antipsychotic 
effect of blocking dopaminergic receptors. They all have this effect to a 
greater or lesser extent, but they interact with other receptors like the 
serotoninergic receptors. There is unanimity in the studies published 
about the effects of these drugs over suicidal ideas. Clozapine in 
particular has been chosen as the most efficient antipsychotic for this 
purpose (Raja M et al., 2014). In our study, 26.1% of the cases and 
62.3% of the controls were taking antipsychotics.  
 
The value of adjusted risk found (OR=0.2; CI 95%=0.1-0.3) gives 
an idea of a remarkable protective effect in those exposed to this 
medication when compared to those unexposed. This effect is of 
enormous interest if we consider that schizophrenia, the condition in 
which this drug is used most frequently, is associated with a greater 
suicide rate and that the suicides have been observed in periods in 
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which the medication has been abandoned or not properly continued 
(Reutfors J et al., 2013). 
 
Numerous studies have identified pain as a cause of suicide, apart 
from the fact that pain can mask a depression (Cheatle MD, 2011; 
Moix J et al., 2011). It seems consistent that pain by itself or as an 
indicator of an illness in its terminal stage might be associated with 
suicide. As a matter of fact, it has been estimated that up to 50% of 
the patients with chronic pain have suicide thoughts (Hitchcock LS et 
al., 1994). In a recent study conducted in Spain, it was observed in 
patients with fibromyalgia (n=180) that there was a positive 
correlation between the degree of pain measured by means of a scale 
and the score obtained in the Plutchik scale that measures suicide risk 
(Pearson’s quotient, 0.51) (Calandre EP et al., 2011). 
 
Analgesics, insofar as they avoid or mitigate the pain, might have a 
protective effect. Opioid analgesics were used in similar percentages 
both in the cases (5%) and controls (4.2%); non-opioid analgesics on 
the contrary were used in a bigger proportion by the cases (60.0%) 
than by the controls (23.9%), so these drugs appear to be a true 
marker of risk. It has been stated that the rise in the consumption of 
analgesics in patients with a history of suicidal behaviour suggests the 
existence of an increase of sensitivity to pain in these patients. (Olié E 
 et al., 2013). In our study, opioid analgesics were associated with a 
protective effect over suicide attempts (OR=0.4; CI 95%=0.2-0.8), 
whereas non-opioid analgesics were associated with an elevated risk 
(OR=4.0; CI 95%=3.0-5.2), the highest risk identified in the analysed 
drugs. The protective effect of opioids that has been identified might 
be a similar real effect, although averaged through different paths, 
than that of ketamine (Autry AE et al., 2011). In any case, the 
protective effect of opioids present in this study is consistent with the 
well-known anxiolytic and sedative effects of these drugs. It is 
noteworthy that this effect has not been described in the literature. 
Less consistent and more difficult to explain is the association between 
non-opioid analgesics and the risk of suicide attempt. The risk should 
be interpreted not as much in the sense that these drugs produce 
suicidal thoughts but because of the prevalence of the use of these 
analgesics among depressive patients more prone to suicidal ideation 
but also in other somatic illnesses, and that the adjustment carried out 
in the analysis has not been capable of avoiding this spurious 
association. The adjustment made has produced a diminishment of the 
risk value but not its disappearance. It should be added that in a high 
proportion of suicide attempts self-intoxication by analgesics is 
employed, so this medication is more present in the cases than in the 
controls. Somatic illnesses associated with pain, as has been said 
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before, are connected with the risk of suicide attempt. 
 
The proportion of smokers among the cases was smaller than among 
the controls (44.5% against 59.2%); tobacco appeared with statistical 
significance as a protective factor (OR=0.6; CI 95%=0.4-0.8). It is 
very common for psychiatric patients to be smokers and even more so 
in the case of patients treated with antipsychotics. If antipsychotics 
exert a protective action over suicidal behaviour and these are 
associated to a greater extent with tobacco use, the distribution of this 
medication found in the cases (26.1%) and controls (62.3%) would be 
consistent with this fact: that apparent protection of tobacco or at 
least part of it might be due to other associated factors like the intake 
of antipsychotics. However, when it is adjusted for possible confusion 
factors, tobacco remains protective as the values of the adjusted 
estimator (OR=0.6; CI 95%=0.4-0.8), although modified, do not differ 
from those of the raw estimator (OR=0.5; CI 95%=0.4-0.7). This 
beneficial effect of tobacco is difficult to explain. Its protective effect 
over the risk to suffer from Parkinson’s is well-known, possibly through 
a stimulating action over the dopaminergic receptors. It does not seem 
possible that this path, at least not uniquely, is involved in suicidal 
behaviour. It must be pointed out that the studies conducted on the 
relationship between tobacco or nicotine and suicidal behaviour have 
 reached contradictory results; while some identified a positive 
association (Yaworski D et al., 2011), others did not (Kessler RC et al., 
2007, Berglund PA et al., 2007; Kessler RC et al., 2009), which 
coincides with our results. These discrepancies might be put down to 
the type of samples studied, that is, the general population against 
population with a psychiatric disorder.  
The other substances of abuse considered, especially cocaine and 
amphetamines, presented higher percentages of consumption in the 
cases. Cocaine in particular, with a consumption percentage of 4.8% in 
the cases and 1.6% in the controls, was associated with a very high 
risk of suicide attempt (OR=3.7; CI 95%=1.6-8.4). When explaining 
suicidal behaviour, the stimulus necessary to execute the action is 
important. This stimulus, undoubtedly, might be produced by cocaine. 
This explanation is in line with one which has been put forward to 
understand the possible action of SSRIs over suicidal behaviour (‘initial 
activation’) (Healy D et al., 1999). Let us not forget that SSRIs and 
cocaine share a similar mechanism in the post-ganglionic nerve 
endings, the inhibition of neurotransmittor reuptake. Finally, cannabis 
had a very similar prevalence of use in the cases and controls, 12.1% 
and 12.9%; in the estimation of adjusted risk there was a higher risk 
of suicide attempts of twice as much associated with this substance 
(OR=2.1; CI 95%=1.3-3.2). This risk coincides with the findings of 
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other recent studies (Delforterie MJ et al., 2015). The deterioration of 
personality and shift to depression produced by its chronic use 
together with its occasional hallucinogenic effect might explain this 
increased risk found.  
 
Both the cases and controls were exposed to benzodiacepines to a 
high percentage, 71.3% and 71.2%, respectively; although it is not 
the aim of our study, the high proportion of use of these substances 
should be cause for critical reflection on the justification of their 
prescription. In our study these substances were not associated with a 
higher risk of suicide attempt. Our results somehow coincide with the 
findings of a meta-analysis about alprazolam and suicidal ideation 
including more than 3,000 patients (Jonas JM et al., 1996). In this 
study alprazolam was not associated with a higher risk of suicidal 
thoughts when compared with different drugs or the placebo. 
Benzodiacepines have been associated in the literature with depression 
and higher mortality (Weich S et al., 2014), however, there is great 
uncertainty in this respect. There is no doubt that, in a similar manner 
to other psychotropic substances mentioned, they are notable 
depressors of the NCS and that their action would depend on dosage. 
It could be said that these drugs, at low doses, behave like anxiolytics 
and, at progressively higher doses, they are hypnotic, sedative and 
 anaesthetic. Although these substances have a very wide therapeutic 
margin, high doses can be lethal and are in fact the cause of many 
accidental or suicidal intoxications with deadly consequences. 
Benzodiacepines have been associated with all kinds of psychiatric 
disorders, for instance triazolam was subjected to strict administrative 
regulation as it was associated with 'criminal behaviour' (Camiñas T, El 
País, 1989; Institut Català de Farmacologia, 1991; Dyer C, 1999); the 
disinhibition it causes could explain this conduct.  
 
Some of the limitations of this study could be the relatively small 
size of the sample, the quality of the information recorded in the 
history and, in general, its retrospective character which has an effect 
on the quality, already mentioned, and the type of information 
included in the histories. In short, the information, although extremely 
useful and in general very comprehensive, was not collected for the 
purposes of this study. As is the case with all observational studies, 
this one is also subjected to the possible existence of biases or 
residual confusion factors due to variables that were not assessed. 
Nevertheless, it should be pointed out that it is difficult to have access 
to such a high number of cases like the ones in our study and that 
having them entails accepting the limitations of the data collection 
usual in healthcare centres. But all in all, the consistence of the 
estimations obtained and the value of the reflection generated by its 
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analysis provides interest to the study. The results are compatible with 
others already obtained and, in this sense, contributes to consolidating 
and qualifying information which is already known. It also provides 
useful data for later studies such as the protective effect over suicide 
attempts of tobacco and the same effect of opioids. 
In essence, our work is fundamentally aimed at the study of the risk 
of suicide attempts associated with medication as well as the study of 
that same risk in the case of addiction substances like tobacco, 
cannabis or cocaine. No symptom, however small it may seem, is alien 
to drugs and, in their habitual use, these drugs have been associated 
with a host of reactions, both somatic and psychic. Besides, the study 
has estimated the risk of suicide attempt by gender, marital status and 
different clinical situations. The estimations obtained are consistent 
with what is already known in the literature and with the natural 
history of depressive illness.  
A family history of suicide and a depression diagnosis are well-
known risk factors which appear as outstanding factors in our study. It 
is worth pointing out as an interesting piece of information the already 
mentioned protective effects of tobacco and antipsychotics and 
opioids, as well as the effect, which should be further analysed, of an 
elevated risk associated with non-opioid analgesics.  
 As recommendations that could be drawn from the study in 
connection with the suicide risk, and with every caution possible, 
would be paying attention to certain situations like social isolation or 
the intake of abuse substances like cocaine and cannabis, the intake of 
SSRI antidepressants in certain circumstances and pathologies 
involving pain. The good calibration of the model with an area under 
the ROC curve of 0.880 offers the possibility of using the variables 
included in the logistic regression for the construction of a risk scale 
that might serve to detect patients presenting a high risk of suicide. 
This way, the pharmacological treatment could be adjusted or modified 
according to the influence of the different risk factors.  
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6. Conclusions 
 
 Suicidal behaviour is a cause for concern due to the rise of its 
prevalence and lethality. Suicide represents one the main causes 
of death in the world.  
 
 Numerous drugs and especially several psychotropic substances 
have been connected with suicidal behaviour.  
 
 Being a woman and social isolation have been associated with a 
greater risk of suicide attempts in our study. 
 
 A family history of suicide and a diagnosis of major depression 
were associated as well with a greater risk of suicide attempts. 
  
 Exposure to SSRI antidepressants, non-opioid analgesics, 
cannabis and cocaine were associated with a greater risk of 
suicide attempts in our study. 
 
 Exposure to antipsychotics, opioids and tobacco was associated 
with a protective effect over the risk of attempting suicide. 
 
 Computer-based clinical histories represent a useful resource in 
pharmacoepidemiological research. Promoting their use for 
research purposes can lead to better healthcare assistance.  
 
 Tracking certain situations such as social isolation, intake of 
abuse substances like cocaine and cannabis, SSRI 
antidepressants in certain situations and pathologies associated 
with pain may prevent suicidal behaviour. 
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8.1. Theories about suicide 
 
8.1.1. Biological models 
 
8.1.1.1. Genetic hypotheses 
 
Nearly half of the patients whose families have had a suicide 
case have also attempted suicide. (Roy A, 1983). As well as the 
psychological mechanisms that could justify this fact (e.g. 
identification with the suicidal patient), genetic factors have 
been put forward. The process by which suicidal conduct would 
be transmitted could be the transmission of the psychiatric base 
illness or the existence of a heritability of the suicidal behaviour 
(Egeland JA et al., 1985; Roy A, 1986). The studies conducted, 
especially with twins, in the Amish population in the USA or 
adopted ones have not cleared the doubts between heritability 
or imitation so as to explain the results.   
 
8.1.1.2. Neurochemical hypotheses  
 
Suicidal behaviour is often attributed to serotonin as a 
neurotransmittor connected with this type of conduct. Several 
proceedings have found a deficit of this substance (postmortem 
tests, measurement of 5-Hydroxyindolacetic acid (5-HIAA) in 
 the Cerebrospinal Fluid (CSF), platelet tests and neuroendocrine 
tests). A decreased amount of 5-HIAA in the CSF has been 
linked with the violence of the suicide act and some authors 
have also linked it with low impulse control, which is consistent 
with similar findings in other related diagnoses (Bobes García J 
et al., 1996). Another line with a great deal of biological 
research is connected with the hypothalamus-pituitary-
suprarenal axis. 17-hydroxycorticosteroids and free cortisol in 
urine, or cortisol in blood or in the CSF have been measured. On 
the other hand, several studies have observed that the patients 
who have tried to take their lives had lower levels of cholesterol 
in plasma (Marcinko D et al., 2007; Brunner J et al., 2002; 
Golier JA et al., 1995; Hawthon K et al., 1993). Consequently, 
cholesterol level in serum might be a risk factor in patients with 
depressive symptoms (Olié E et al., 2011). 
 
8.1.2. Psychological models 
 
8.1.2.1. Psychoanalytic theories 
 
Freud placed the problem of suicide in the centre of the 
human soul. In Mourning and Melancholia (Freud S, 1917) he 
describes suicidal impulses as homicidal, aimed at the object 
loved previously introjected. Karl Menninger reproduced Freud's 
Appendices 
175 
 
concepts on suicide. (Menninger K, 1938). He highlighted three 
hostile pulsions present in suicide: the wish to kill, the wish to 
be killed and the wish to die. For Litman, there are other factors 
to take into account apart from hostility: guilt, anxiety, 
dependence (Litman RE, 1967). 
 
8.1.2.2. Psychosocial theories 
 
Although not unique, Emile Durkheim's theories are a decisive 
contribution from the field of sociology to the understanding of 
the suicide phenomenon. His studies in the 19th Century, 
among the modern investigations on the topic, are 
groundbreaking. He has had an influence on all modern studies, 
even from different standpoints. For Durkheim, already in 1897 
(Durkheim E, 1982), suicide is ruled by the interaction between 
society and the individual. He distinguishes three main types of 
suicide, depending on the relationship between man and 
environment. In altruistic suicide, individuals decide to put an 
end to their lives for the benefit of society and certain rules and 
situations that so demand it: to carry on with life would be 
unacceptable (‘hara-kiri’ would be an example of this). 
Egotistical suicide, on the contrary, is an individual decision 
against society, whose norms they do not reach. This would 
 explain why suicide is more frequent among single people. 
Anomic suicide responds more to the abrupt breakdown of the 
mechanism that maintains the person integrated into society, 
the loss of habitual rules: suicides after economic catastrophes, 
for instance (Schmidtke A et al., 1996). 
 
 
8.2. Evaluation of the suicidal patient 
 
Confronting a person with suicide ideas or who has attempted 
suicide provokes psychic discomfort in the professionals. They 
have to handle such discomfort because most of the times this 
will interfere with the treatment. As a result, it is important to 
hightlight several mistakes which are common in dealing with 
suicidal persons in order to avoid them (Table 9). 
 
In spite of the fact that it is not easy to create an adequate 
atmosphere for dialogue in the context of an Emergency Unit or 
Primary Care Centre, the most important thing is to create an 
adequate setting, a peaceful atmosphere, without interruptions, 
where the patient can feel confident and safe.   
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Table 10; Mistakes about suicide 
 
 All suicides are mentally ill 
Those who talk about killing themselves do not carry it out 
It is good to have a patronizing or moralistic attitude 
It is not bad to get infected by the sick person’s pessimism 
One should not ask questions about suicidal ideation 
Manipulative efforts should not be taken seriously 
 
 
8.2.1. Anamnesis and exploration 
 
When the patient is ready to take the interview, 
psychopathological exploration should take place. It is advisable 
to let the patient talk. In order to achieve this, open questions, 
not hurtful, must be asked but without avoiding diving into the 
suicidal ideation or act. The following paragraghs are dedicated 
to reasonable steps to take. Initially, the patient's conventional 
medical history must be obtained, with special interest in the 
data considered risk factors (e.g. chronic or disabling organic 
illnesses) (Kaplan HI et al., 1999). Besides, a detailed 
psychiatric history will be written, searching for the psychiatric 
diagnoses which are most closely associated with the suicide 
acts, especially depression. The suicidal behaviour or ideation 
 originates from some psychic, existential, familial or social 
crisis, if not psychiatric. It is fundamental to know the 
circumstances which trigger the attempt. It is also crucial to 
know the suicidal behaviour, if it takes place, in detail and 
particularly important to identify any psychosocial crisis, so 
often associated with suicide attempts, especially 'dyadic' crises 
(e.g. with a love partner o a parent) that might precipitate the 
act. Psychopathological exploration, in the case of persons with 
suicidal intent, pursues the exploration of the autolythic 
ideation. Much could be said about this but, in order to provide 
a clear scheme, we will follow Clark and Fawcett's work (Clark 
DC et al., 1992). These authors classify suicidal patients in 
accordance with the immediacy of the suicide act: the lowest 
risk is assigned to those who do not have suicide thoughts. A 
greater risk is assigned to those who have passive ideation 
(they wish to die), even more risk for those who have active 
ideation (they wish to kill themselves) and finally, the highest 
risk is assigned to those who think about a method to 
consummate suicide. It seems interesting to include here the 
recommendations of the World Health Organization in the CIE-
10 for primary care, for the correct assessment of the suicide 
patient (WHO CIE 10, 1996): 
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1. Evaluation of the suicide risk in an immediate future: 
 
a)  Suicide ideation (sporadic against persistent) 
b) Intent (the suicide is a possibility or the patient has already 
decided it?) 
c) Suicide plan (the more elaborate the plan, the greater the risk and 
even more so if resources are available). 
d)  Loneliness (poor family or social support). 
e) Alcohol (it limits self-control). 
f) Social difficulties (marginalization, unemployment, Durkheim's 
anomy) 
 
2. Evaluation of a patient with a recent suicide attempt: 
 
a) ¿Was the chosen method dangerous? 
b) ¿Did the patient believe that the method was going to work? 
¿Were they surprised to have survived? 
c)  ¿Was it possible to be discovered? 
d)  ¿Were they relieved to be saved? 
e)  ¿Was the patient trying to get a message across or did they only 
want to die? 
f)   ¿Was it an impulsive or planned attempt? 
g) ¿Have the life and psychological circumstances that determined 
the attempt changed? 
 
     
 
A correct assessment of a suicidal patient must include an 
interview with the family or persons who are important to the 
patient. In that interview, data of the previous history of the 
patient, their psychopathology and the attempt details, if this 
has taken place, must be collected. Of course, it is necessary to 
try to obtain the family's cooperation, if an outpatient treatment 
is required.  
 
 8.2.2. Assessment of suicide risk 
 
From a dynamic point of view, we all have, inherently to our 
nature, suicide wishes to a greater or lesser extent. Thus, any 
person has contemplated the possibility of committing suicide or 
has carried out an act that has put their life at risk. However, it 
cannot be considered that all those persons will commit suicide 
one day. According to Shneidman, the main aim of evaluating a 
person with suicide ideas, whether they have attempted it or 
not, is to determine their lethality, that is, establish the 
mortality of the suicide ideas or acts (Shneidman ES, 1971). 
Although there is consensus about the fact that somebody who 
commits suicide or attempts it is not in a good condition, it is 
possible that suicide may occur with a minimum of psychic 
disturbance and, as a result, making it impossible to specify a 
psychiatric diagnosis. On the other hand, patients undergoing 
profound psychopathological crises might carry out autolythic 
attempts of very low lethality. So, when it comes to assessing 
the patient, it is important to bear in mind that the degree of 
lethality is not proportional to the type and intensity of psychic 
disturbance.   
In order to assess lethality and suicide risk, one must have a 
sociodemographic and behavioural profile connected with a 
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higher risk in accordance with the associated risk factors. In 
spite of the fact that the professional must consider the data 
present in the patient which are statistically associated with a 
higher suicide risk, they must always consider that the 
intrapsychic factors are predominant when it comes to assessing 
the patient's vulnerability (Buda M et al., 1990). As Rives says, 
the evaluation of these patients is an art and cannot be reduced 
to a list (Rives W, 1999). Bearing this in mind, the person with 
more dangerous suicide ideation tends to have meditated the 
decision for long. He also shows signs that the doctor, often 
from Primary Care Centres or an Emergency Unit, must be able 
to recognize (Shneidman ES et al., 1970). Normally these 
persons are very agitated and frequently depressed. Many of 
them will mention their intentions, invalidating the general belief 
among many doctors that those who announce it do not execute 
it. Frequently, there will be changes in the eating, sexual or 
sleep habits of the patients. Especially alarming is the fact that 
the patient parts with objects which are very valuable to the 
person.  
 
It is also interesting to assess the degree of suicide intent. As 
opposed to the unmistakable determination to commit suicide 
by some persons and which is of course associated with a high 
 risk, there are many suicide attempts where the main wish 
appears to be changing one's own life or that of significant 
persons more than ending one’s life. The most dangerous 
psychological characteristics present in suicide ideation are: the 
short duration of the ‘suicide crisis’ since a sick person might be 
agitated for a long period of time but will rarely have a high-risk 
suicide ideation for a long time before either they become 
exhausted or carry it out; the ambivalence towards the fact of 
death, often wishing to die and being saved at the same time 
and the presence of 'another person' and suicide as a dyadic 
act.  
 
8.2.3. Suicide methods 
 
The suicide methods employed are quite diverse. The greater 
or lesser lethality of the method often depends on accessibility 
to the self-harm mechanism. Consequently, restricton of access 
to the most common suicide methods constitutes a necessary 
and useful prevention tool (Ajdacic-Gross et al., 2007). Some of 
the most commonly used methods are: precipitation, hanging, 
asphyxia, medication intoxication, gas intoxication (inhalation), 
poisoning with plants, mushrooms, metals, cleaning products 
and pesticides, starvation, suspending the prescribed 
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medication, provoked traffic accidents, throwing oneself in front 
of vehicles (car, train, lorry...), shot by firearm, bomb in 
explosive belt, self-immolation, swallowing sharp or cutting 
objects, self-stabbing or eventration (Maris, Berman and 
Silverman, 2000; Asociación de Investigación, prevención e 
Intervención del Suicidio, 2009). In the choice of method to 
carry out the suicide act, sociocultural and even geographic 
influence (sea, railway, farming area-pesticides) plays a role 
since the geographic area is connected with access to tools to 
facilitate suicide (Morales y Jiménez, 1996). A tendency has 
been recorded in some countries to replace traditional methods 
with death by pesticides or gunshot. Pesticides were commonly 
used in Asian countries and South America whereas medication 
intoxication was more common in Nordic countries and the 
United Kingdom. Hanging was the preferred method in Eastern 
Europe and firearms in the USA and jumping out of a window in 
cities and urban societies like the Special Administrative Region 
of Hong Kong, China. Lester (Lester, 1971) classified the 
methods as active like hanging, precipitation, firearms, knives 
and passive like gases, drugs or poisons. In the same line, 
Isometsa et al., (1994) consider suicide by hanging, gunshot, 
knife, precipitation and train run-over as violent and suicide by 
 drowning, gases, toxic substances, drugs or poisons as non-
violent. Maes y et al. (1994) add as violent the suicides by 
explosives and sharp instruments while they consider drowning 
as non-violent. Altamira and other authors (1999) on the other 
hand include traffic accident within the group of violent suicides 
and the intake of solid or liquid substances as non-violent 
methods. The males tend to choose active methods (gunshot, 
precipitation or hanging) while the females opt for passive 
methods (poisoning). The method classification as violent or 
non-violent is in keeping with the impulsivity of the suicide act. 
A stressful life event might generate a crisis that leads to an 
impulsive suicide attempt. It is essential in order to create 
strategies and prevention programmes to have information 
about the habitual suicide methods. 
 
 8.2.4. Therapeutic attitude 
 
The first aim before patients who have hurt themselves is to 
treat the effect of the aggression. This aspect includes the 
treatment of the intoxication, whatever it may be, closing the 
wound in the forearm, etc. Once this is done, the following step 
is to ensure the patient's safety.  
The attitude before a suicidal patient could be the traditional 
Appendices 
185 
 
one between a therapist and a sick person (Shneidman ES, 
1982). The doctor may appear more empathic, active, showing 
their intention to understand the patient's situation. It is no time 
to appear cold, neutral or critical and it is worth getting involved 
more than usual. This does not exclude having a firm attitude 
inspiring confidence (Sarró B et al., 1991). A first diagnosis of 
the psychiatric illness, if applicable, must have been made. It is 
therefore compulsory to initiate, recover or correct the 
psychopharmacological treatment of the illness. The most 
common drugs are antidepressants (Bousoño García M et al., 
1997) since they are effective in order to diminish impulsivity 
and aggressiveness as well as the depressive mood. It is 
convenient to choose antidepressants whose hazard level in 
case of intoxication is lower. The help of the family is a key 
factor in order to store and administer the medication correctly. 
In general, any person with suicidal ideation or any type of 
suicidal conduct should be assessed by a psychiatrist. The 
period of time in which the doctor should provide   psychiatric 
evaluation, will depend on the clinical characteristics of the 
patient and the healthcare service possibilities. In a great deal 
of cases, the suicide act does not seek death and it is of very 
low lethality. It is the case of the so called “parasuicides” that 
 can even be a cathartic act which may improve the state of the 
patient or give rise to a more favourable family or relationship 
situation. On those occasions the doctor should understand that 
the urgency of the specialised evaluation does not exist. In 
cases or greater lethality, the patient should be seen by a 
psychiatrist urgently. Here, the most important decision is 
whether or not to hospitalise the patient. On the whole, 
hospitalisation of the suicidal patient will cause associated 
problems and besides, the doctor cannot ignore the fact that 
there will never be enough beds so as to admit any person with 
suicide ideas. Apart from the evaluation of the suicide risk of the 
patient and according to all of the above, the main factor to 
bear in mind in an outpatient treatment is the capacity of the 
own individual to acquire the commitment to seek assistance if 
they reach a critical point. It is also important to count on the 
family’s support and important persons for the sick person 
(Arranz Estévez FJ, 1997). 
 
8.2.5. Summary 
 
As it has been recognized by the World Health Organization, 
suicide is a major problem of public health. In Spain, where the 
proportion of suicides has traditionally been low, it is increasing 
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with the passage of time. There are sociodemographic data 
statistically related with a higher suicide risk. Men have a higher 
suicide risk while women have a greater number of attempts. 
Suicide is more usual in old people and attempt in young 
people. Single, separated, divorced and widowed people have 
more suicide risk statistically as well as unemployed people and 
those with lower education. Suicide is more frequent in the 
north of Europe and among city dwellers. The most reliable 
aspect to predict suicide is the presence of previous autolythic 
attempts. In a high percentage of cases, suicidal people also 
suffer from organic illnesses with chronic or disabling diseases 
involving a higher risk. People who try to commit suicide are in 
a difficult psychic and/or social situation. Although many of 
them do not suffer from any mental disorder, the majority of 
those who complete suicide do. The psychiatric disorder which is 
most frequently diagnosed is major depression. The suicidal 
phenomenon has been analysed by researchers from every 
scientific paradigm. Biological investigations have been carried 
out: genetic studies of various types or neurobiochemical, 
mainly related to serotonin; psychoanalytic which focus on 
unconscious aggressiveness; or psychosocial, above all 
Durkheim’s influential theories. Nowadays the tendency is to 
 consider ‘multidimensional’ models which try to integrate 
several theories. In the evaluation of a suicidal patient it is basic 
to control the anguish that these patients frequently provoke to 
avoid taking wrong steps. It is necessary to have a complete 
clinical history, analyse a possible psychopathology previous to 
the attempt, know the details of the suicidal act if it has been 
produced and carry out a good psychopathological exploration, 
paying special attention to the presence and dangerousness of 
the suicidal ideation. In order to assess and prevent suicidal 
risk, the doctor will have to evaluate sociodemographic and 
behavioural data that are statistically associated with a high 
risk, but without forgetting the lethality of the ideation or the 
attempt in accordance with the intrapsychic factors of the 
patient. For this purpose, health professionals should look out 
for the signs of a possible suicide offered by the patient, the 
degree of suicidal intent or the existence of the typical 
psychological characteristics of the suicidal ideation. Family 
participation is key when it comes to assessing and dealing deal 
with the patient (Kposowa AJ, 2001). The attitude of the 
therapist must be empathic, understanding and firm. Once the 
organic damage, if it exists, has been treated, the main goal is 
the patient’s safety. Many self-harm acts are not real psychiatric 
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emergencies and should not be treated as such. If there is a 
psychiatric disease, it should be treated in the mid and long 
term. In suicide attempts of high lethality, it is the psychiatrist 
who should decide if hospitalisation or outpatient treatment is 
recommended (Stenager EN et al., 1994). 
 
8.3. Clinical history 
 
The development of information systems in health care is 
modifying certain aspects of the clinical practice, causing 
changes which will require the participation and consensus of all 
health care professionals in the future. There is no doubt that 
the clinical history is a central element of the patient’s medical 
information and a communication channel among the different 
health professionals caring for the patient. For a number of 
years, most hospitals have had a very useful tool, a computer-
based or electronic clinical history. It is important that the 
collection of the terminological information in the computer-
based clinical history is previously defined in order to process it 
and make the most of it later on. For the processing of 
terminological information in the electronic clinical history, there 
are documentary-based languages which allow to classify and 
codify every illness. The future tendency is the compilation of 
 the different documentary-based languages allowing the 
professional not only to navigate through the clinical history, but 
also access bibliographical databases and help tools for the 
decision making. The role of the electronic clinical history for the 
quality of health care has been the topic of numerous 
pubications with different results because of methodological 
problems. The most important beneficial effects are connected 
with a greater adhesion to the clinical practice guidelines and 
the decrease of mistakes made in the control of the medication 
(González E et al., 2007). In a recent study comparing the 
information collection between the paper histories and the 
computerised ones, it was observed that, in terms of precision 
and comprehensiveness, the most complete information was 
obtained from the electronic records in comparison with the 
paper records. However, in both types of systems deficiencies 
were observed in the documentation systems for the studied 
pathology (Tubaishat A, et al, 2015).  
 
In our study, the computer-based clinical history had all the 
information relative to the hospital admissions not only in the 
Psychiatry Unit but also in other medical departments. Besides, 
it also included the outpatient visits to the specialised assistance 
practices and a number of visits to Emergency that the patients 
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had made. Also, not only were the clinical diagnoses included, 
but also the pharmacological treatments prescribed to every 
patient. In the case of the patients who had committed a suicide 
attempt prior to 2005, the paper histories were used. These 
histories practically included the same information, although the 
data collection was more laborious. 
 
8.4. MCMI-III (Millon Multiaxial Clinical Inventory  III) 
 
Theodore Millon (1928-2014) contributed to the study of 
personality disorders in the DSM-III, a structure which has 
evolved into the DSM-5. His 1969 book, Modern 
Psychopathology, created a theoretical framework which 
facilitated the understanding of the known personality 
prototypes. His theoretical work soon led to the creation of 
several psychological inventories, Millon Multiaxial Clinical 
inventory (MCMI), being the best known and most used (Choca 
JP, et al., 2015). For more than 35 years, the personality model 
and the MCMI have been very useful resources, used by 
professionals to understand and assess personality disorders 
and clinical syndromes in psychiatric patients (Strack S, et al., 
2007). The original inventories (MCMI-I; Millon, 1977 and 
MCMI-II), were gradually refined through theoretical 
 investigations. The new Millon Clinical Multiaxial Inventory-III 
(MCMI-III; Millon, 1994) was coordinated even more with the 
diagnostic scheme of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) in an even more explicit way.  
 
The current version of MCMI, the MCMI-III, reinforces these 
theoretical correspondences, making use of many of the 
diagnostic criteria of DSM-IV (and current DSM-5) to serve as a 
basis in the drafting of the inventory articles (Millon T., et al, 
1997). MCMI-III provides empirically validated information, 
relevant and reliable to support the diagnosis of psychiatrists 
and other mental health professionals in different areas; clinical, 
medical, forensic, etc.   
 
This questionnaire consists of 4 indices that enable the 
assessment of the protocol validity and 24 clinical scales 
grouped in accordance with the level of severity: clinical 
patterns of the personality, serious pathology of the personality, 
clinical syndromes and serious clinical syndromes. MCMI-III is 
not a general personality instrument to be used with healthy 
individuals or with a different purpose other than psychological 
evaluation. Neither is it advisable to be used among the 
adolescent population. 
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*Source: adapted from MCMI-III, 2014 
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8.5. Additional tables 
 
 
Table 11.  Previous suicide attempts among the cases  
 
Gender  
  Male Female 
Total   N % N % 
Previus 
attempt 
yes/no 
No 144 79,6% 89 23,5% 233 41,6% 
Yes 37 20,4% 290 76,5% 327 58,4% 
Total  181 100,0% 379 100,0% 560 100,0% 
    
    
    
    
    
 
 
 
 
 
 
  
 
Table 12.  Personality of the cases (percentage for men and 
women). 
 
 
Gender 
Total 
Male Female 
N % N % N % 
P 
e 
r 
s 
o 
n 
a 
l 
i 
t 
y 
Antisocial 4 2.2% 7 1.8% 11 2.0% 
Dependent 29 16.0% 55 14.5% 84 15.0% 
Schizoid 10 5.5% 22 5.8% 32 5.7% 
Schizotypal 10 5.5% 15 4.0% 25 4.5% 
Avoidant 3 1.7% 6 1.6% 9 1.6% 
Histrionic 10 5.5% 7 1.8% 17 3.0% 
Borderline 107 59.1% 250 66.0% 357 63.8% 
Narcissist 1 0.6% 5 1.3% 6 1.1% 
Obsessive 3 1.7% 2 0.5% 5 0.9% 
Paranoid 4 2.2% 10 2.6% 14 2.5% 
Total 181 100.0% 379 100.0% 560 100.0% 
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Table 13.  Suicide methods used by the cases. 
 
 
Gender 
Total 
Male Female 
N % N % N % 
Type of 
autolythic 
attempt 
Medication 
Intox. 
84 46.4% 229 60.6% 313 56.0% 
Defenestration 12 6.6% 16 4.2% 28 5.0% 
Self-injury 56 30.9% 112 29.6% 168 30.1% 
Gas Intox. 6 3.3% 11 2.9% 17 3.0% 
Hanging 13 7.2% 5 1.3% 18 3.2% 
Drowning 2 1.1% 2 0.5% 4 0.7% 
Others 8 4.4% 3 0.8% 11 2.0% 
                         Total 181 100.0% 378 100.0% 559 100.0% 
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8.6. Publications related to the study 
 
 
- Fármacos anticonvulsionantes analgésicos y conducta 
suicida. Trabajo final de máster en Investigación en 
Ciencias de Salud. Universidad de Valladolid. Facultad de 
Medicina, 2012. 
 
 
- Premio Sancho Valázquez Cuéllar por la comunicación 
formato póster: “Psicotropos y comportamiento suicida” 
presentada en la VXII Reunión Asociación Castellano 
Leonesa de Psiquiatría el 19 de octubre de 2012 
 
 
- Fármacos y conducta suicida: Estudio de Casos y 
Controles; comunicación oral presentada en la VXII 
Reunión Asociación Castellano Leonesa Psiquiatría del 18 al 
20 de octubre de 2012. 
 
 
- Fármacos y conducta suicida: un estudio de casos y 
controles; Autores: Ana Fructuoso Castellar, Manchón 
Asenjo MJ, Alfonso Carvajal García-Pando;  Antonio 
Escudero García;  Natalia Jimeno Bulnes; Encuentros en 
psiquiatría, 12 y 13 de abril de 2013. 
 
 
- Psychotropics and suicidal behaviour- a case-control study; 
European Psychiatry; Volume 28, Supplement 1, 2013, 
Pages 1; Abstracts of the 21th European Congress of 
Psychiatry. 
  
 
 
 
 
 
- Personalidad, consumo de fármacos y conducta suicida: un 
estudio de casos y controles; Ana Fructuoso Castellar; 
Alfonso Carvajal García-Pando;  Antonio Escudero García;  
Natalia Jimeno Bulnes; X Congreso Nacional de 
Personalidad, 23-25 de abril de 2014, Barcelona. 
 
- Analgesics and suicidal behavior: a case-control study; 
Autores: A. Fructuoso Castellar, A. Carvajal García-Pando, 
A. Escudero García, N. Jimeno Bulnes; XVI World Congress 
of Psychiatry, 14-18 de septiembre de 2014, Madrid. 
 
- Suicide attempt and medications. A retrospective case-
control study; Autores: Fructuoso A,  Fierro I, Jimeno N, 
Carvajal A. Centro de estudios sobre la seguridad de los 
medicamentos (CESME), Universidad de Valladolid (Sevilla, 
3 y 4 de octubre de 2014). 
 
 
 
